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Abstract 
 
Chronic pain represents one major health problem of today’s global society. Some 
treatments fail and still many aspects of chronic pain development and maintenance 
are unknown. Here, we present new insights into the Ca2+ signalling behaviour of acute 
slices of murine spinal cord dorsal horn astrocytes and parvalbumin(PV)-positive 
neurons. To our knowledge we showed here for the first time that stimulation of 
preferred fibre classes from the dorsal root evokes Ca2+ signalling in the cytosol and 
nucleus of astrocytes and the cytosol of PV-neurons. In addition, we detected a 
decrease of these evoked Ca2+ signals under neuropathic pain conditions when 
stimulated with Aβ- or Aδ-fibre preferred frequencies. We did not observe differences 
under chronic inflammatory pain conditions, neither in astrocytes nor in PV-positive 
neurons. Further investigation showed that the Ca2+ signalling dependent immediate 
early gene Npas4 was reduced 3 days after neuropathic pain induction and that 
overexpression of NPAS4 in spinal dorsal horn neurons in vivo, leads to a rescue of 
mechanical but not thermal hypersensitivity. These findings suggest an important role 
of the Ca2+ signalling behaviour of astrocytes in response to Aβ- and Aδ-fibre 
stimulation under neuropathic pain under the tested conditions. Especially because of 
the occurrence of Ca2+ signalling in the astrocytic nucleus, we propose a similar gene 
regulation function as in neurons, which probably induce plasticity changes in 
astrocytes. This might be due to adaption to the neuronal activity required to transmit 
signals from the periphery to the brain, which is possibly disturbed under chronic pain 
conditions. Thus, the purpose of astrocytes to support those changes in pain 
conditions would also require changes in signalling behaviour. In addition we 
hypothesize an important role of NPAS4 regulation in the spinal cord dorsal horn under 
neuropathic pain conditions, primarily to control the inhibition of pain stimuli. 
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Zusammenfassung 
Chronische Schmerzen sind ein großes Gesundheitsproblem der Weltgesellschaft. 
Einige Behandlungen scheitern und viele Aspekte der chronischen 
Schmerzentwicklung und -erhaltung sind immer noch unbekannt. Hier präsentieren 
wir neue Einblicke in das Ca2+ -Signalverhalten von Astrozyten und Parvalbumin (PV) 
-positiven Neuronen im spinalen dorsalen Horn in akuten Schnitten von Mäusen. 
Unseres Wissens nach zeigen wir hier zum ersten Mal, dass die Stimulierung 
bevorzugter Nervenfaserklassen aus den sensiblen Nervenwurzeln Ca2+ -Signale im 
Zytosol und im Zellkern von Astrozyten und im Zytosol von PV-Neuronen hervorruft. 
Zusätzlich haben wir eine Abnahme dieser hervorgerufenen Ca2+ -Signale unter 
neuropathischen Schmerzbedingungen festgestellt, wenn sie mit Frequenzen, die 
bevorzugt diese Fasern Aβ- oder Aδ-Fasern anregen, stimuliert wurden. Wir haben 
keine Unterschiede unter chronischem Entzündungsschmerz beobachtet, weder in 
Astrozyten, noch in PV-positiven Neuronen. Weitere Untersuchungen zeigten, dass 
die Expression des Ca2+ -Signal-abhängigen unmittelbare frühe Gen Npas4 an drei 
Tagen nach neuropathischer Schmerzinduktion reduziert war und dass eine 
Überexpression von NPAS4 in Neuronen des Hinterhorns in vivo zu einer Rettung der 
mechanischen, aber nicht thermischen Überempfindlichkeit führt. Diese Ergebnisse 
legen eine wichtige Rolle des Ca2+ -Signalverhaltens von Astrozyten als Reaktion auf 
Aβ- und Aδ-Faserstimulation unter neuropathischen Schmerzen, abhängig von den 
getesteten Bedingungen, nahe. Insbesondere aufgrund des Auftretens von Ca2+ -
Signalen im Zellkern von Astrocyten schlagen wir eine ähnliche 
Genregulationsfunktion wie in Neuronen vor, welche wahrscheinlich 
Plastizitätsänderungen in den Astrozyten zur Folge hat. Dies könnte auf die 
Anpassung an die neuronale Aktivität zurückzuführen sein, die zur Übertragung von 
Signalen von der Peripherie zum Gehirn erforderlich und die unter chronischen 
Schmerzbedingungen möglicherweise gestört ist. Daher würde der Zweck von 
Astrozyten, diese Veränderungen der Schmerzzustände zu unterstützen, auch 
Veränderungen des Signalverhaltens erfordern. Zusätzlich nehmen wir an, dass die 
NPAS4-Regulation im Hinterhorn des Rückenmarks unter neuropathischen 
Schmerzzuständen eine wichtige Rolle spielt, vor allem, um die Inhibition der 
Schmerzsignale zu kontrollieren. 
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1. Introduction 
“When you get to the end of your rope, tie a knot and hang on.” This quote, originally 
said by Theodor Roosevelt, reflects what many chronic pain patients suffer from every 
day. Chronic pain is a severe symptom of known or sometimes unknown reasons. It 
costs patients and their relatives and friends, who often suffer with their beloved ones, 
much strength and power of endurance. Many patients suffer from the fact that they 
are often misunderstood, because chronic pain is something one cannot see, 
something other people cannot understand or feel. If people see someone who has a 
broken leg, they feel sympathy for that person. But an apparently healthy person, 
without any visible disability might be confronted with disbelief or even ignorance. On 
top of that, the frustration of not being able to treat the chronic pain and not being able 
to escape leads to depression, altered concentration or addiction (Boersma et al. 
2019).  
For society chronic pain and other diseases caused by chronic pain, for example 
depression or opioid-addiction, lead to many other problems as well. Money is only 
one of those reasons. For example in the United States of America in 2010 the 
estimated costs were at $560 to $635 billion (Gaskin and Richard 2012). And 
unfortunately there are no good long-term treatments at the moment. Scientists put a 
huge amount of effort into investigating causes, development and maintenance of 
chronic pain in order to find possible treatments. Sometimes it is possible to heal the 
original cause, the injury, but the pain remains. Why is that? What drives the 
development of chronic pain? Why do some patients do not even respond to analgesic 
treatment? And when patients react positively to analgesics, they face the long-term 
problem of addiction or insensitivity to the drug. Also mental problems like depression 
itself or post-traumatic stress can cause chronic pain. Both, stress and chronic pain 
seem to share similar mechanisms (Abdallah and Geha 2017). We still need to 
understand many different aspects of how the central nervous system (CNS) works 
and why it develops chronic pain. Pathways still have to be unravelled. 
 
1.1. The mechanism of pain – from skin to brain 
Pain is supposed to be a protective mechanism, acting as a warning system in case 
of tissue damage and the immediate reaction to avoid more damage to the body. Even 
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inflammation, which seems to be an annoying status of pain, ensures that we reduce 
movements or stress onto the inflamed body part so that we give the tissue time to 
recover. Responsible for the sensation of pain are so called nociceptors, thinly 
myelinated Aδ-fibres and unmyelinated C-fibres, transmitting the stimuli from the 
periphery into the dorsal horn of the spinal cord, forming synapses with neurons and 
glia cells. The approximate diameter of Aδ-fibres lies between 1 - 5 µm and the signal 
transmission speed of their action potentials at 5 – 35 m/s. For C-fibres, which are not 
myelinated, the diameter is very thin, between 0.2 and 1.5 µm. Their action potentials 
travel at a speed around 0.5 – 2 m/s. These fibres can detect different stimuli through 
a huge variety of receptors, expressed in their peripheral terminal ends. For example, 
some of their many receptors react to ATP, prostaglandin, serotonin or capsaicin. After 
detecting painful stimuli through those receptors, the signal can be transmitted into the 
cell body, located in the dorsal root ganglion, where it can initiate gene expression. 
This gene expression might increase the synthesis of neuropeptides that will be 
released in the central terminal of the fibres which build synapses in the spinal cord 
dorsal horn. Here the signal is transmitted to neurons in different dorsal horn layers 
via diverse neurotransmitters, chemokines, cytokines and neuropeptides, but mainly 
through glutamate, substance P and brain-derived growth factor (BDNF) 
(Gangadharan and Kuner 2013). In the dorsal horn itself, the received signal from the 
periphery might or might not be transmitted directly or indirectly to projection neurons 
in the superficial layer of the dorsal horn and then forwarded to the brain. For the 
sensitisation of pain in the brain, there is not one single brain region responsible, but 
several which fulfil different aspects of how one feels pain. Under acute pain or 
physiological pain conditions these signals are further transmitted to the thalamus and 
then ending in the pariental lobe of the cerebal cortex. Further involved brain regions 
are, for example, limbic regions and the amygdala, involving emotions into the 
sensation of pain.  The hippocampus seems to be involved as well, in the context of 
pain and memory, for example in the context of aversive conditioning (Basbaum and 
Woolf 1999). But under specific conditions this acute pain can develop into a chronic 
pain. Even peripheral terminals that are responsible for light touch-sensation, Aβ-
fibres, can develop from non-noxious into noxious fibres. Those large diameter (about 
6 – 12 µm), thick-myelinated fibres are responsible for light-touch sensations that are 
transmitted very fast to the dorsal horn (35 – 75 m/s) but can, for example after 
inflammation, start to express substance P, which will be transmitted to dorsal horn 
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neurons and thus send a signal which will be understood and transmitted as pain 
instead of “light-touch”.  
The different fibres from the periphery innervate the spinal cord dorsal horn in different 
layers. Aδ nociceptors project for example to lamina I and the deeper lamina V into 
the dorsal horn. The touch-fibre Aβ on the other hand forms synapses in laminae III-
V. Finally, C-fibres project into the superficial laminae I and II (Basbaum and Braz 
2010) (Fig. 1). But this is not an exclusive structure. As reviewed for example by 
Gangadharan and Kuner (Gangadharan and Kuner 2015), the spinal pain circuits are 
not yet clearly described. Just parts of it get unravelled bit by bit. For example Duan 
and colleagues (Duan et al. 2014) show that excitatory somatostatin positive 
interneurons in lamina II receive input from Aβ-fibers. Those neurons are then 
connected to projection neurons in lamina I. Also in lamina III, where Aβ-fibres build 
synapses with glutamatergic neurons, these signals are then transmitted into more 
superficial layers to excitatory as well as to inhibitory neurons (Peirs et al. 2015). 
Figure 1: Afferent fibres innervating spinal dorsal horn. Graphical scheme represents 
one hemisphere of the spinal cord from the lumbar area 3 – 5. Peripheral fibres, Aβ-fibres 
(blue), Aδ-fibres (green) and C-fibres (yellow), with cell bodies in the dorsal root ganglion, 
entering and forming synapses in the different laminae of the dorsal root of the spinal cord. 
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For a patient pain is defined as chronic when the symptoms endure longer than six 
months (Merskey 1994; Treede et al. 2015) . In this case the pain persists for a long 
and undefined period of time of suffering, even when the initial caise of the pain (like 
dysfunction or damaged tissue of the periphery, inflammation, tumour invasion or due 
to diabetic consequences) is solved or healed. An increased sensation to painful 
stimuli is called hyperalgesia and a pain sensation to normally non-painful stimuli is 
defined as allodynia. This maladaptation to pain is caused by a dynamic development 
of neural and glial plasticity in the periphery and the CNS, thus also inside of the dorsal 
horn of the spinal cord. 
This chronic pathological condition can be divided into two groups. On the one hand, 
there is inflammatory pain which is often induced by tissue damage. On the other hand, 
there is neuropathic pain where the somatosensory nervous system is altered by a 
lesion or disease. Both types of chronic pain conditions show the characteristics of the 
mentioned hyperalgesia, allodynia or both (Woolf and Salter 2000).  
 
1.1.1 The spinal cord dorsal horn and its cells 
To understand the changes in the mechanisms of the development and the 
maintenance of chronic pain, it is important to have a look at all the different key 
players. Chronic pain can unfortunately not be decreased by treatment of peripheral 
nociceptors only. This is because of the central sensitisation which happens in the 
dorsal horn of the spinal cord. This central sensitisation is similar yet not equal to 
activity dependent changes of synaptic transmission, described ad long-term 
potentiation (LTP) or long-term depression, in the higher brain regions like plasticity 
changes for example in learning and memory processes in the hippocampus (see 
section 1.2.2 Ca2+ induced synaptic plasticity). Yet the central sensitisation also 
consists of plasticity changes of synapses and the increased expression of 
transmitters, eventually adaptions or even loss of functions. Those changes are often 
coupled to Ca2+ signalling changes, similar to LTP in the hippocampus. More 
information about Ca2+ is provided in a later section (see 1.2 Ca2+ - An universal 
messenger). 
In the spinal cord dorsal horn, the largest group of neurons are glutamatergic neurons, 
which actively transmit the sensory signal from the periphery to the brain. These 
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excitatory neurons are controlled by inhibitory interneurons, the second type of 
neurons in the spinal cord dorsal horn that use gamma aminobutyric acid (GABA) or 
glycine as neurotransmitters (Todd 2010, 2017). These interneurons silence the 
glutamatergic neurons to make sure that not every spontaneous signal is transmitted 
as painful (Basbaum and Braz 2016). Here might already lie a hint for a destructive 
system when the inhibitory interneurons become dysfunctional. In fact, it has already 
been discussed, that impairment of the inhibitory system, like a loss of function of 
GABAergic neurons, would cause a so-called disinhibition. This would finally result in 
increased pain (Melzack and Wall 1965; Basbaum et al. 2009; Takazawa and 
MacDermott 2010b, 2010a) as the excitatory signals would not be under control 
anymore.  
Other cells present in the spinal cord are glia cells such as astrocytes and microglia. 
Astrocytes became of increasing importance in the last two decades as their assumed 
simple supportive role for neurons turned out to be an underestimation. Microglia are 
known to be activated under pain conditions (Tsuda 2016). Moreover, microglia are 
believed to have a major role in the mechanism of chronic pain as within hours after 
injury, microglia accumulate and release gliotransmitters like BDNF or cytokines like 
interleukin-6 (Basbaum and Braz 2010; Tawfik et al. 2007). Furthermore, microglia 
express receptor channels such as transient receptor potential (TRP) channels that, 
when stimulated, lead to Ca2+ influx into the cells (Echeverry, Rodriguez, and Torres 
2016). Those channels are known to be involved into neuropathic pain development. 
In addition, it is also known, that microglia can respond to neuronal activity and 
neurotransmitter with mitogen-activated protein kinases (MAPK) pathway (Ji and 
Strichartz 2004), which in return induces gene expression, responsible for plasticity 
changes. Thus, microglia can be activated and change plasticity under pain conditions. 
 
1.1.1.1 Glutamatergic neurons 
Glutamatergic neurons represent the largest population of neurons in the CNS. As 
their name already indicates, this type of neurons release glutamate. As major 
neurotransmitter glutamate activates predominantly postsynaptic amino-3-hydroxy-5-
methyl-4-isoxazole propionate (AMPA), kainite, metabotrobic glutamate receptors and 
NMDA receptors. For the fast neurotransmission the ionotropic AMPA receptor 
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channel are the major key players. After glutamate binding the AMPAR channels are 
opened and the postsynaptic cell is depolarized by the Na+ influx.  If the depolarisation 
is strong enough an action potential is evoked and the postsynaptic cell in turn is 
transmitting the signal to connected neurons. The glutamate activation of NMDA, 
kanaite, metabotrobic receptors and some AMPA receptor subtype are used to modify 
the response of the postsynapse to presynaptically released glutamate. Here the influx 
of Ca2+ ions through NDMA and AMAPR subtypes and the release of intracellular Ca2+ 
ions has a dominating function. 
In the context of chronic pain it has been shown that excitatory neurons react with 
increased Ca2+ signalling under chronic pain conditions when the dorsal root is 
stimulated in acute spinal cord slices (Simonetti et al. 2013) . This goes into the 
direction of central sensitisation of dorsal horn neurons, referring to hyperexcitability 
which results in enhanced pain sensitisation ((Woolf 1983), (Basbaum et al. 2009), 
(Sandkuhler 2009)). Also the involvement of AMPA receptors was already shown 
(Gangadharan et al. 2011) to be involved in inflammatory pain in mice. The authors 
showed that deletion of AMPA receptors in nociceptors as well as blocking AMPA 
receptors with antagonists led to decreased hypersensitisation under acute and 
chronic inflammatory pain. The excitatory signal from the periphery was therefore not 
transmitted to other excitatory neurons in the spinal cord dorsal horn. This result shows 
that excitatory transmission of signals in the pain circuits is important for the 
sensitisation of pain. As already mentioned, this signal is normally controlled by 
inhibitory neurons, silencing for example spontaneous activity of excitatory neurons. 
For the so-called central sensitisation in the spinal cord dorsal horn caused by 
stimulation of C-fibres also NMDA receptors have been shown to be involved ((Woolf 
and Salter 2000) (Drdla and Sandkuhler 2008) (Basbaum et al. 2009)). The activation 
of the NMDA receptors increased the glutamatergic signal transmission- memory in 
the hippocampus. This seemed to be more important for chronic pain than for acute 
pain (Liu et al. 2008) . There LTP induces through NMDA receptors permanent 
plasticity changes. This is comparable to the central sensitisation in the dorsal horn. 
Furthermore, it was shown that blocking NMDA receptors in the spinal cord lead to 
decreased pain sensitisation. 
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1.1.1.2 GABAergic neurons 
Activated neurons that inhibit action potentials of other cells by hyperpolarisation are 
called inhibitory neurons. In contrast to glutamatergic neurons, they release GABA or 
glycine, a transmitter responsible for the formation of hyperpolarisation of the 
postsynaptic cell and thus contributing to their silencing. Those inhibitory neurons are 
therefore called GABAergic neurons. In general these kinds of neurons are important 
for controlling and preventing the excitability of a cell system.  
Overall, the inhibitory system plays a key role in the context of chronic pain. It is 
believed, that neuropathic pain is established because of an impaired inhibitory 
network. Thus, it seems to be of even more interest in the spinal cord. Here the 
excitatory signal is already “filtered” by inhibition through the dorsal horn cell circuit 
before the signal is transmitted to the brain. Therefore, investigating inhibitory neurons 
specifically in the spinal cord dorsal horn provide with important details about the 
sensory regulation system before any information is passed to the brain.  
The loss of inhibitory function in the context of chronic pain is called “disinhibition”. 
This loss of function of inhibitory interneurons was already shown very early to 
increase pain sensitisation (Melzack and Wall 1965; Basbaum and Braz 2010). 
Alan Basbaum and Joao Braz showed described in their review (Basbaum and Braz 
2016), that transplanting inhibitory precursor cells from cell culture into the spinal cord 
dorsal horn can reduce pain sensitisation. Transplanting embryonic medial ganglionic 
eminence (MGE) cells, from GABAergic interneurons are derived, into cerebral cortex 
and spinal cord showed that inhibitory neurons, tested positive for GABA for example, 
developed axons and dendrites and also migrated successfully into the tissue. The 
studies are an example that the altered inhibition of the tissue, either seizure- or 
peripheral nerve injury-dependent, can be restored by MGE cell transplants. The cells 
showed good survival and built functional connections to other neurons within the 
tissue.  
In vivo tests even showed that mice recovered from spared nerve injury (SNI) to 
baseline mechanical sensitivity when transplanted with MGE cells after SNI surgery, 
compared to the control group which received only medium injection and developed 
hypersensitivity. The level of GAD expression, which is a marker for inhibitory neurons 
and normally altered after SNI induction, also reaches baseline levels again after the 
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MGE cell transplant. Interestingly, it only reached baseline, so a functional recovery 
and did not developed uncontrolled inhibition. 
Thus, in central sensitisation, an increase of excitatory activity, combined with a 
disinhibition, seems to play a central role in the development and possible the 
maintenance of maladaptive pain sensitisation. 
This thesis will concentrate on parvalbumin (PV), a calcium-binding protein, positive 
inhibitory neurons. These GABAergic neurons are represented in the spinal dorsal 
horn. They distribute mainly in laminae II – III (Zacharova and Palecek 2009; 
Zacharova, Sojka, and Palecek 2009; Antal, Freund, and Polgar 1990; Ren and Ruda 
1994; Yamamoto et al. 1989) . Zacharova et al. already showed that there was a 
reduction of PV-positive GABAergic neurons in the superficial dorsal horn laminae 
under peripheral inflammatory conditions. Other groups suggested no role of 
GABAergic neurons from the spinal dorsal horn in neuropathic pain models. For 
example, Gassner and colleagues (Gassner et al. 2013) found no changes in the 
excitability of GABAergic neurons in spinal laminae III between naïve and neuropathic 
pain induced animals. 
That this area is still under debate makes it even more important for further 
investigation into the role of GABAergic cells in the spinal dorsal horn and the 
development and maintenance of different pain conditions. 
 
1.1.1.3 Astrocytes – more than just “the glue” 
Among neurons, we find glia cells in the spinal dorsal horn. The biggest group of glia 
cells are the astrocytes. Although glia-derived mediators were described to be 
powerful modulators of excitatory and inhibitory signal transmission and are described 
to be involved in the central modifications underlying pain the exact role in pain 
sensation is not resolved (Gosselin et al. 2010; Ji, Berta, and Nedergaard 2013). In 
the 1990s, the discovery of cytoplasmic Ca2+ signals in astrocytes that were induced 
by released neurotransmitters that would activate G protein-coupled receptors 
(GPCRs), changed the estimated role of astrocytes in the CNS for the first time. 
Before, glial cells, including astrocytes, were believed to be a simple supportive cell 
type for neurons. Astrocytes were there to transport nutrients from the blood vessels 
to neurons and to stabilize the tissue. Due to the discovery of GPCRs in the astrocytic 
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membrane, it was discovered that there was more to astrocytes. Apparently, they were 
able to react to Ca2+ signals released from the inner calcium store of the endoplasmic 
reticulum (ER). When, for example, ATP would bind the GPCR and lead to inositol 
1,4,5-triphosphate-3 (IP3) activation, which would then bind to IP3 receptors in the ER 
membrane, that would lead to a Ca2+ release from the ER into the cytoplasm of the 
astrocyte. Those Ca2+ signals were described as calcium waves through the 
astrocytes. Still, the importance of Ca2+ in astrocytes and its effect on neurons is very 
controversial. Some groups see differences in early stages of learning and memory, 
when astrocytic Ca2+ signalling is altered (Semyanov 2019), while others do not. For 
example, Agulhon and colleagues (Agulhon, Fiacco, and McCarthy 2010; Fiacco et al. 
2007; Agulhon et al. 2008)  tested the impact of astrocytic Ca2+ signalling on pyramidal 
neurons in the CA1 region of the hippocampus. They did not see an effect on the 
behaviour or dynamics of neuronal Ca2+ signals when astrocytic Ca2+ was blocked.  
Furthermore, it has been shown that the fine processes of astrocytes have Ca2+ 
signals that do not always reach the soma of the astrocyte and that the Ca2+ signalling 
dynamics in the processes can be very different from the ones in the soma. This was 
for example shown in Itpr2-/- mice (mice with disturbed Ca2+ release from internal 
stores), where there were no alteration of Ca2+ signals in the processes but in the 
astrocytic soma (Srinivasan et al. 2015)  . Other studies have even shown that the 
Ca2+ driven communication between neurons and astrocytes can be independent from 
astrocytic soma Ca2+ signalling but involve only Ca2+ communication of astrocytic 
endfeet and processes (Szokol et al. 2015; Panatier et al. 2011) . These findings 
already indicate how diverse the Ca2+ signalling in astrocytes can be and how the 
different types of signalling might serve different purposes. 
The amount of other receptors expressed in the astrocytic membrane made clear that 
there is much more to astrocytes than only being “the glue” of CNS tissue. The fact 
that astrocytes can, through different receptors, sense GABA, glutamate, TRPA1 and 
even cannabinoids, shows that they definitely contribute to the signalling pathways in 
the CNS. Guerra-Gomes and colleagues (Guerra-Gomas et al. 2018) nicely reviewed 
the many different inputs that would cause inner Ca2+ rises in astrocytes and the output 
following that stimulation. The review was mainly based on data from the 
hippocampus. Inhibitory and excitatory input from neurons onto astrocytes would lead 
to a Ca2+ rise in the astrocytic cytoplasm and then lead to the release of 
17 
 
gliotransmitters, like BDNF, glutamate, ATP, or D-serine, among others. This release 
can in turn influence the synaptic activity of neurons and thus the signalling cascade. 
This is why in the past years the term “tripartite synapse” has been established 
(Araque et al. 1999). This term refers to the astrocytes as a third part of the classical 
pre- and post-synapse formation, surrounding the synaptic cleft of neurons. 
One tool to label astrocytes is through the glial fibrillary acidic protein (GFAP), which 
is an intermediate filament protein that is mainly expressed in the cytoplasm of 
astrocytes in the CNS (Brenner et al. 1994). GFAP immunostaining is commonly used 
to identify astrocytes. For example astrogliosis, a reactive state of astrocytes, was 
measured by an increase of number of GFAP positive cells as well as astrocytes after 
brain injury, peripheral injury, plaque formation in Alzheimer’s disease, genetic 
disorders or chemical insult (Eng, Ghirnikar, and Lee 2000). The activation of 
astrocytes is also called reactivation and astrogliosis, which both refers to an increase 
of the cell body volume, thicker processes and strong proliferation. 
This activation is directly connected to an increase in GFAP positive cells. An 
upregulation of GFAP and a hypertrophy of astrocytes has already been shown under 
some pain conditions. Normally, a certain gliosis is beneficial for recovery after brain 
injury but excessive gliosis and its associated neuroinflammatory responses will have 
a negative impact on the structural and functional recovery of affected brain tissue 
(Sofroniew 2009). This effect of astrogliosis can also be caused, for example, by 
spared nerve injury (SNI) or intraplantar injection of complete Freund’s adjuvant 
(CFA). Activation of astrocytes is also linked to ATP-dependent chronic pain (Chessell 
et al. 2005) , suggesting that Ca2+ signalling in astrocytes plays a major role in the 
establishment and maintenance of chronic neuropathic and inflammatory pain. 
One form of how reactive astrocytes involved in gliosis can influence chronic pain 
modifications in the spinal cord circuits, is through increasing release of 
gliotransmitters like chemokines, which then enhances the excitatory synaptic 
transmission (Zhang, Jiang, and Gao 2017) . As the process of astrogliosis and 
transmitter release might be Ca2+ -dependent, it is worth investigating the role of Ca2+ 
signalling in astrocytes under chronic pain conditions. Surprisingly little is known about 
nuclear Ca2+ signalling in astrocytes, even though it might be obvious that it happens 
and leads to altered gene transcription, just like in neurons. Gene transcription and 
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protein expression would then lead to the increased growth of astrocytic processes. 
There are only very few published studies that investigate whether the Ca2+ signalling 
in astrocytes functions in the same way as it does in neurons. It has been shown that, 
for example, Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) (see section 
1.2.1 Ca2+ from induction to other cell compartments) is expressed in astrocytes and 
increased when they are stimulated, which then leads to expression of BDNF (Liu, 
Zhang, et al. 2017). This indicates a similar reaction pathway of astrocytic Ca2+ signals 
just like in neurons, where Ca2+ signalling into the nucleus leads to gene transcription. 
To summarize, not much is known about the Ca2+ signalling of astrocytes in the spinal 
cord, especially under chronic pain conditions. Even less is known about nuclear Ca2+ 
signalling. However a recent study showed that spinal cord dorsal horn astrocytes 
release GABA in response to synaptic activation (Christensen et al. 2018), which might 
promote astrocytes are potential therapeutic targets in pain control.  
Thus, the role of astrocytes needs further investigation in order to understand the 
neuron-glia interaction in the spinal circuits and its central sensitisation under chronic 
pain conditions. 
Figure 2: Chronic pain models and their development. Graphical scheme represents the 
time course of pain sensitivity development of SNI surgery, causing neuropathic pain (green) 
and CFA injection, responsible for chronic inflammatory pain (blue). 
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1.1.2 Animal pain models 
To investigate chronic pain, it is not always possible to work with patients. Especially 
discovering the underlying molecular and cellular pathways requires animal models. 
There are a few established models that demonstrate different chronic pain conditions. 
For neuropathic pain, one model has been shown to be quite reproducible: spared 
nerve injury (SNI). This model comes with different modifications and names. In 
principle, nerve branches from the periphery of the hind paw, leading to the lumbar 
part 3 – 5, are damaged in a way that remaining branches develop a hypersensitivity. 
The developing neuropathic pain increases over the first few days, reaching a peak 
and plateau at day 7, and lasts for many weeks (Fig. 2). The mice then avoid stressing 
the neuropathic paw too much and the paw appears to be cramped. 
Chronic inflammatory pain is often represented in animal models with complete 
Freund’s adjuvant (CFA). The heat-shocked Mycobacteria tuberculosis cause the 
release of cytokines and other inflammatory signals in the periphery and thus lead to 
inflamed tissue. The paw appears swollen, red and warm. The chronic inflammatory 
pain after CFA injection is already established several hours after injection and 
increases until reaching a peak of hypersensitivity at 24 h after injection (Fig. 2). 
 
1.2 Ca2+ signalling – An universal second messenger 
The occurrence of Ca2+ ions as second messengers is transversal in nature. Due to 
its chemical and physical characteristics, this cation can form complexes with many 
proteins, inducing activity changes in many signalling pathways (Clapham 2007). One 
of the most important ways to transmit information from cell to cell and to induce 
structural changes via gene transcription is through Ca2+ signalling, as will be 
explained in detail in the next subsections. 
In order to sensibly interact with their environment, living beings must sense stimuli. 
Furthermore, they have to transmit and analyse every stimulus to make favourable 
decisions. They can even store and recall these events as information when they are 
useful to face new situations. The central nervous system (CNS) plays a major role in 
all those vital functions. Different parts of the CNS are responsible for processing 
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different inputs and producing specific outputs, establishing communications within 
their own tissue as well as with many other regions. 
The neurons in the CNS convey information through action potentials, and these 
action potentials always initiate the activation of different Ca2+ signalling pathways, 
including those responsible for the release of neurotransmitters. For example, 
glutamate can bind to N-methyl-D-aspartate (NMDA) or amino-3-hydroxy-5-methyl-4-
isoxazole propionate (AMPA) receptors and induce a Ca2+ influx from the extracellular 
matrix into the cytoplasm of the neuron. Ca2+ can easily enter the nucleus of cells 
through nuclear pore complexes and act upon gene transcription. In the following 
section, I will go into more detail concerning how gene transcription is induced and 
what role different cell compartments play in Ca2+ signalling. 
 
1.2.1 Ca2+ from induction to other cell compartments 
The cytoplasmic concentration of Ca2+ in resting cells lies at ~100 nM and the cell 
keeps that level by actively exporting Ca2+ ions from the intra- to the extracellular 
space via plasma membrane calcium ATPases and sodium-calcium exchangers 
(NCXs). Another way to keep the Ca2+ concentration in the cytosol at a steady level is 
through take-up into the endoplasmatic reticulum (ER), which is a major intracellular 
calcium store. Through sarcoendoplasmic reticulum calcium ATPase (SERCA) 
pumps, which are located in the membrane of the ER, Ca2+ is actively transported form 
the cytosol into the ER.   
Action potentials can induce an influx of Ca2+ ions from the extracellular space into the 
neuron, through voltage-gated calcium channels (VGCCs). Other ligand binding 
receptor-channels, like AMPA and NMDA receptors, drive Ca2+ entry causing a 
dramatic local rise of Ca2+ concentration up to ~1 - 2 mM and thus mirror the activity 
state of the cell. After Ca2+ has entered the intracellular space, it binds to calmodulin. 
The Ca2+/calmodulin complex can then bind and activate Ca2+/calmodulin-dependent 
protein kinase kinase (CaMKK). The activated CaMKK can then bind and 
phosphorylate, among others, Ca2+/calmodulin-dependent protein kinase IV (CaMKIV) 
which can freely enter the nucleus through nuclear pore complexes (as well as 
Ca2+/calmodulin itself) and phosphorylates cyclic AMP response element binding 
protein (CREB) through the histone acetyltransferase CREB binding protein (CBP). 
21 
 
This complex can finally induce transcription of specific genes (Bading 2013; 
Hagenston and Bading 2011). 
To shortly summarize, activity-dependent Ca2+ signalling in the neurons induces a 
cascade of events, leading to the formation of complexes that can freely enter the 
nucleus of the cells and induce gene transcription by binding transcription factors. The 
resting Ca2+ concentration in the nucleus is the same as in the cytosol, as the nuclear 
envelope does not represent a barrier for Ca2+ ions and the ions can freely pass the 
nuclear envelope through the nuclear pore complexes.  
As already mentioned, the ER represents an internal store for Ca2+ and can release it 
when ER-resident Ca2+ channels like IP3 receptors or ryanodine receptors (RyR) are 
activated. Inositol triphosphate 3 (IP3) production is activated by stimulation of the G 
protein-coupled receptors (GPCRs), which then activates phospholipase C (PLC) 
which in turn cleaves phosphatidylinositol-4,5-biphsphate to IP3, the second 
messenger responsible for activating IP3 receptors. Through these mechanisms and 
the SERCA pumps, the ER contributes to buffer and shape the Ca2+ signalling inside 
a cell (Berridge 1998). As the ER distributes throughout the whole cell, from dendrite 
to active zones in the axon, it is a key player in the transmission of Ca2+ signals from 
the periphery of the cell to the soma, where the nucleus is. Through Ca2+ “waves” that 
go the whole way via the ER, synapse stimulation can then cause nuclear Ca2+ 
signalling (Watanabe et al. 2006).  
Mitochondria also play an important role in neuronal Ca2+ signalling. Not only are they 
important for the energy support that is needed near the synapses, but they can also 
store Ca2+ ions. Ca2+ ions are imported and exported through uniporters and 
mitochondrial Na-Ca-exchangers (mNCXs). Thus, mitochondria can buffer the 
cytosolic Ca2+ concentration. Furthermore, Ca2+ stimulates mitochondrial ATP 
synthesis by activating the tricarboxylic acids cycle (Marchi et al. 2018). But if the 
function of mitochondrial Ca2+ buffering is disturbed and too much Ca2+ ions are 
transported into sand accumulated in the mitochondria, this can induce apoptosis. 
Thus, one of the most important roles of Ca2+ signalling in neurons is to regulate gene 
transcription in the nucleus. But what is the function of gene transcription in neurons? 
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1.2.2 Ca2+ induced synaptic plasticity  
One major function of nuclear calcium signalling is neuroprotection. For example, the 
activation of NMDA receptors in the hippocampus leads to expression of 
neuroprotective genes (Papadia et al. 2005). Papadia and colleagues transferred 
hippocampal cell cultures from growth medium into basal medium to induce cell death. 
This effect was rescued by blocking GABAA receptors with bicuculline to indirectly 
activate synaptic NMDA receptors. They showed compelling evidence that long-
lasting neuroprotection is nuclear Ca2+ signalling- and CREB activation-dependent.  
Nuclear Ca2+ signalling is involved in learning and memory formation processes. For 
example, the blockade of CaMKIV in the forebrain causes impaired memory 
consolidation in mice (Limback-Stokin et al. 2004; Kang et al. 2001). One gene, whose 
expression is induced by nuclear Ca2+ signalling, is for example vascular endothelial 
growth factor D (VEGFD). This growth factor appeared to be crucial for contextual fear 
conditioning (Mauceri et al. 2011). In learning and memory, the development of 
plasticity changes such as increased spine density are crucial, and many genes 
needed for these processes are Ca2+ signalling-dependent. Long-term potentiation 
(LTP) is a phenomenon caused by frequent neuronal activation, which induces NMDA 
receptor stimulation and results in boosted Ca2+ signalling. It is known that LTP is 
crucial for learning and memory processes. LTP induces expression of genes through 
frequent Ca2+ influx and thus nuclear Ca2+ signalling, which leads to persistent 
plasticity changes (Bengtson et al. 2010). Bengtson and colleagues evoked nuclear 
Ca2+ signals by stimulating CA1 pyramidal neurons from hippocampus in acute mouse 
brain slices with established transcription-dependent late LTP-inducing stimulation 
protocols.  
 
1.2.3 Maladaptation of Ca2+ signals in pathogenesis and pain 
Even though Ca2+ signalling is a major messenger in the CNS, responsible for crucial 
plasticity changes in memory formation and neuroprotection, it can also become a 
problem.  
Drug addiction is one example, for when memory formation, LTP and thus initially Ca2+ 
signalling becomes a problem instead of a supportive system in the CNS. It has been 
shown that addiction is a malfunction of the reward system, involving persistent 
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structural and functional changes in regions involved in addiction (Bading 2013; 
Hyman, Malenka, and Nestler 2006). 
It is also suggested that Ca2+ signalling driven plasticity changes occur also in chronic 
pain, just as they do in memory formation (Ji et al. 2003). In addition, it has been shown 
that Ca2+ signalling is increased in, for example, excitatory neurons (Bading 2013; 
Simonetti et al. 2013). But in general, research concentrated mostly on Ca2+ signalling 
in learning and memory formation and, related to that, drug addiction and its 
involvement plasticity changes. Very little is known about the role of Ca2+ signalling in 
chronic pain development and maintenance. 
 
1.2.4 How to investigate Ca2+ signals  
All these studies have been achieved by using tools to detect Ca2+ signalling in cells. 
One good and reliable tool is the use of genetically encoded calcium indicators 
(GECIs). GECIs can be expressed specifically in different cell types, depending under 
which promoter the GECI is inserted. By binding calcium/calmodulin to the M11 motif 
of the GECI, the protein changes its conformation, which leads to an increased 
fluorescence of the bound GFP construct. Bengtson et al. 2010 showed for the first 
time the expression of GECI in the nucleus of neurons by combining the Ca2+ sensor 
GCaMP with three copies of a nuclear localisation signal (NLS). They showed that 
action potentials cause Ca2+ signalling in the nucleus of pyramidal neurons in the CA1 
of the murine hippocampus.  
Other localisation signals can be used in combination with these indicators, in order to 
investigate different cellular compartments. For example, by adding a nuclear export 
signal (NES), the localisation of the indicator can be ensured to be outside the nucleus 
and in the cytosol of the cell only. Another way would be to bind the indicator to the 
membrane in order to investigate processes or axons in their Ca2+ signalling 
behaviour, as the cytoplasm localised indicator would be mainly visible in the soma of 
the cell due to the high volume-to-surface ratio. The binding to the membrane can be 
done by expressing the indicator fused to a lymphocyte-specific protein tyrosine kinase 
(Lck), which is a membrane bound kinase. 
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1.3 Npas4 
Neuronal PAS Domain Protein 4 (NPAS4) is an immediate early gene (IEG) and 
transcription factor (TF). It belongs to the basic-helix-loop-helix (bHLH)-PER-ARNT-
SIM (PAS) family of transcription factors, which contain a bHLH domain for DNA 
binding and tandem PAS domains for dimerization and protein-protein interactions. 
NPAS4 is expressed in excitatory neurons and diverse types of inhibitory neurons, like 
somatostatin-, parvalbumin- or 5HT3a-positive cells. In both cell types, Npas4 is 
induced by neuronal activity, specifically via nuclear Ca2+ signalling (Zhang et al. 2009) 
. In all these cell types, NPAS4 regulates the expression of other IEGs in response to 
stimulation and neuronal activity. Spiegel and colleagues (Spiegel et al. 2014) showed 
that Npas4 is expressed in cortical cultures after stimulation with high potassium 
levels. NPAS4 induction in all cell types leads to Npas4-dependent induction of other 
IEGs like FosB, another transcription factor which regulates other genes in order to 
induce plasticity changes in neurons (Nestler, Kelz, and Chen 1999). Similar results 
were achieved in vivo with sensory input through light stimulation to mice that were 
kept for a certain time in the dark. Unlike the IEGs, only about 25 % of expressed late-
response genes happen to be in both cell types (excitatory and inhibitory neurons), for 
example: Nptx2 and Gpr that are involved in the synthesis of AMPA and GPCRs (Fig. 
3 A) (Spiegel et al. 2014). Strikingly, many other late-response genes were regulated 
by NPAS4 in a cell type-specific manner. For example, in excitatory neurons, NPAS4 
regulates the induction of Bdnf which then promotes synaptic growth and is known to 
be involved in synaptic plasticity changes (De Vincenti et al. 2019). In inhibitory 
neurons, on the other hand, NPAS4 induces the expression of genes like Frmpd3 and 
Rerg which are involved in synaptic density and signal transduction (Lee, Tsang, and 
Birch 2008). 
As Bloodgood and colleagues (Bloodgood et al. 2013) showed in their previous work 
that the number of inhibitory synapses onto the soma of pyramidal neurons is 
regulated and increased by NPAS4 expression in vivo and that a knockout of NPAS4 
in mice decreases the number of inhibitory synapses onto excitatory neurons in the 
hippocampus, Spiegel et al. determined the different synaptic inputs onto the distinct 
cell types. To investigate the distribution of different synapses onto the distinct cell 
types, they labelled inhibitory synapses with the specific marker Gad65/GABAARβ2/3 
and Synapsin 1/PSD 95 for excitatory synapses. They counted the amount of 
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synapses and discovered an increased number of inhibitory synapses onto excitatory 
neurons, confirming Bloodgood and colleagues’ results, and an increase of excitatory 
synapses onto inhibitory neurons when NPAS4 was increased in those cell specific 
cultures or their decrease, when NPAS4 was knocked down (Spiegel et al. 2014). 
The conclusion from this work is that through expression of distinct genes in excitatory 
and inhibitory neurons leads to a change in plasticity and synaptic dynamics in those 
cells. They showed that in cortical tissue, activity-induced NPAS4 regulates the 
number of inhibitory synapses on excitatory neurons and excitatory synapses onto 
inhibitory neurons. Thus, activity-induced NPAS4 promotes the inhibitory influence in 
the neuronal circuit. Spiegel and colleagues suggest a homeostatic influence of 
NPAS4 in cortical and hippocampal regions. 
As already mentioned for the work of Bloodgood and colleagues, NPAS4 plays an 
important role in the hippocampus. Here, normal house kept mice didn’t show 
detectable NPAS4 expression, but when housed in environmental enrichment cages, 
the mice showed an increase of NPAS4 expression. Further, NPAS4 knockout mice 
showed reduced inhibitory postsynaptic currents compared to the controls. This 
indicated the role of neuronal activity induced NPAS4 in the balance of inhibitory input 
onto excitatory neurons in the hippocampus. Other groups have also shown that 
NPAS4 is important, for example, in contextual memory formation (Sun and Lin 2016; 
Ramamoorthi et al. 2011). 
Another study showed that in the hippocampus NPAS4 is induced in pyramidal 
neurons by sensory experience, which then selectively enhances somatic inhibition 
through recruiting inhibitory synapses from cholecystokinin-expressing basket cells 
(Hartzell et al. 2018). Activity-induced NPAS4 regulates an increase of basket cell 
synapses onto the soma of pyramidal cell in the CA1 of the hippocampus. 
This means that in the context of learning, memory and experience-driven neuronal 
activity, NPAS4 is important in the regulation of inhibitory input onto pyramidal cells. 
This together with the study in the cortical regions by Spiegel et al., indicates that 
NPAS4 represents an important key player in the regulation and control of neuronal 
circuits, balancing the system in an inhibitory manner in different brain regions (Fig. 3 
B). 
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In the context of its important role in promoting inhibitory input onto the CNS, when 
activated, it might well be possible that impaired NPAS4 expression is involved in 
cognitive disorders. In some cognitive disorders like schizophrenia and autism (Ung 
et al. 2018) the inhibitory system of the CNS is dysfunctional, meaning less inhibitory 
neurons and synapses or expression of GAD65 and GAD67. In schizophrenia for 
example, the expression of the number of parvalbumin positive neurons is altered in 
the prefrontal cortex. It was just recently shown that NPAS4 is decreased in 
parvalbumin positive interneurons in a model of schizophrenia, where neonatal mice 
were treated with the NMDA receptor antagonist ketamine (Shepard et al. 2019). In 
this study, schizophrenia-like behaviour in mice, such as hyperactivity and social 
deficits, were caused by a knockdown of NPAS4. 
The role of Npas4 is not yet well described. In fact, one study examined the function 
of NPAS4 in environmental enrichment-mediated responses in the hippocampus 
under neuropathic pain. Wang and colleagues demonstrated, for instance, that 
neuropathic pain, caused by chronic constriction injury (CCI), a ligation of the sciatic 
nerve, leads to a dysfunction of NPAS4 expression in the hippocampus (Wang et al. 
2019).  
As mentioned above, chronic pain can also cause depression and memory 
impairment. Wang and colleagues investigated not only the expression of NPAS4 in 
the hippocampus under neuropathic pain, but also the involvement of environmental 
enrichment. It is already known that environmental enrichment decreases 
hypersensitivity under neuropathic pain and thus represents a possibility for 
therapeutic intervention. When Npas4 expression was decreased under neuropathic 
pain, environmental enrichment was no longer able to “rescue” the positive effect onto 
pain sensitivity, depression-like behaviour or memory deficit under neuropathic pain. 
Furthermore, the expression of tumour necrosis factor (TNF)-α under neuropathic pain 
indicates inflamed brain tissue. In addition, increased Npas4 also decreased the 
expression of TNF-α on protein levels. 
In conclusion, the exact role of Npas4 in chronic pain is not yet clear. Especially in the 
spinal cord tissue, which, in contrast to the hippocampus, plays a more central part in 
the pain circuit, nothing specific is known so far about how Npas4 regulates the 
neuronal circuit or how it might be involved in the transmission of painful sensory input. 
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In total, there are not many published studies about Npas4 in the context of chronic 
pain or the spinal cord but as it is responsible for promoting inhibitory balance in 
neurons in the CNS, like the cortex or the hippocampus, it becomes more and more 
worth to investigate. 
As mentioned above (see section 1.1.2.2 GABAergic neurons), GABAergic synapses 
and thus inhibitory neurons of different types are already shown to be impaired in their 
function or reduced in their number under chronic pain also in the spinal cord. 
Recently, it was discovered that a preoperative stress leads to reduced NPAS4 
expression and might be linked to postoperative hyperalgesia in the spinal cord of rats 
(Wu et al. 2019). In this study, the authors measured postoperative hyperalgesia after 
the implementation of preoperative stress. Here, increase of glucocorticoid under 
hyperalgesia also comes along with synaptic plasticity changes, like decreased 
GABAAα-1, GABAAγ-2, GAD65 and GAD67. These are known to be regulated by 
NPAS4 and support the inhibitory circuit in the CNS, as they are markers for inhibitory 
synapses. By reducing corticosterone with antagonists, Wu and colleagues were able 
Figure 3: Npas4 regulates gene expression and plasticity changes. (A) Schematic 
example of late-response genes that are regulated by NPAS4. Inhibitory neurons (green) 
express for example Rerg and Frmpd3 in an NPAS4-dependent manner. Excitatory 
neurons (orange) express for example Bdnf and Csmpl in a NPAS4-dependent manner. 
Both cell types express genes like Nptx2 and Gpr3 in a NPAS4-dependent manner. All 
those genes promote synaptic dynamics and plasticity. (B) An increase of NPAS4 in 
inhibitory neurons (green) results in increase of excitatory synapses onto the inhibitory 
neuron and an increase of NPAS4 in excitatory neurons (orange) leads to an increased 
amount of inhibitory synapses onto the excitatory neuron. 
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to rescue the expression of NPAS4 and GABAergic markers after stress induced 
postoperative hyperalgesia. They further showed that overexpression or knock down 
of NPAS4 through intrathecal rAAV injection either reduced hyperalgesia (for 
overexpression) or increased hyperalgesia sensation (for knock down of NPAS4 with 
rAAV-Npas4 RNAi). Their constructs for manipulating NPAS4 expression also 
influenced expression of GABAergic markers. Overexpression of NPAS4 led to 
increased GABAergic markers, whereas injection with the NPAS4 RNAi led to reduced 
GABAergic markers. 
Thus, Npas4 represents an interesting target for further research, as it regulates genes 
that are important for inhibitory input onto excitatory neurons and the excitatory input 
onto inhibitory neurons, resulting in an increase of inhibitory function in the CNS (Fig. 
3). As the inhibitory system is reduced or impaired in its function under chronic pain 
conditions (see section 1.1.2.2 GABAergic neurons) it is necessary to investigate 
NPAS4 in the context of the mechanisms of chronic and acute pain. The question of 
whether chronic pain is linked to impaired NPAS4 expression is still unsolved. It might 
be, as other authors already suggested, that Npas4 represents a possible target for 
pain treatment. 
 
Aims of this thesis 
As presented in the introduction, the spinal cord dorsal horn has many different cell 
types, neurons as well as glial cells that respond with Ca2+ signalling to synaptic 
activity. Chronic pain has been shown to include Ca2+ signalling in excitatory neurons 
in the laminae I-II of the spinal cord dorsal horn. As shown above, glial cells as well as 
inhibitory neurons have already been shown to be altered by increased or decreased 
activity under chronic pain models. Thus, it makes sense to ask for the role of Ca2+ 
signals in those cells and their different cellular compartments. Figure 1 shows the 
different main cell types in the dorsal horn of the spinal cord. Mechanisms and 
functions are all about communication between different cell types and their alterations 
in case one player changes its behaviour. So how does Ca2+ signalling change, for 
example, in astrocytes and inhibitory neurons (Fig. 4)? This thesis will therefore 
concentrate on the following goals: 
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1. As astrocytes are known to react to different transmitters with Ca2+ signalling 
and as it is also known that astrocytes react with gliosis under chronic pain, do 
these two things change together? Does chronic inflammatory as well as 
neuropathic pain have an influence on Ca2+ signalling in different cellular 
compartments? In this thesis, I concentrated on astrocytic Ca2+ signals, evoked 
by electrical stimulation of the dorsal root in acute slices. I used GECIs to 
investigate the signal in the cytoplasm, the membrane and the nucleus. I further 
investigated the signal changes under different chronic pain conditions. 
2. Another interesting target would be Ca2+ signalling in inhibitory neurons. As 
shown above, inhibitory neurons like parvalbumin positive cells, play already 
an important role under chronic pain conditions. Excitatory neurons respond 
with increased Ca2+ signalling under chronic pain conditions. What about 
parvalbumin positive neurons? Electrically evoked Ca2+ responses in 
parvalbumin neurons were so far not described in spinal cord dorsal horn. In 
addition, would the Ca2+ signalling be altered under chronic pain?  
3. As already mentioned in the introduction, one gene draws our attention, as it is 
induced by synaptic activity and Ca2+ signalling: Npas4. It is responsible for an 
excitatory-inhibitory balance in the CNS, favouring inhibition and some studies 
indicate that increased pain is coupled to decreased Npas4 and decreased 
GABAergic synapses. So in the last part of the thesis I will investigate the role 
of Npas4 in the spinal cord dorsal horn under chronic and acute pain conditions. 
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Figure 4: Involvement of different cell types and their Ca2+ signalling in the spinal dorsal 
horn under chronic pain conditions. Schematic drawing represents introduction of chronic 
pain conditions concerning the lumbar part L3 – L5 of mice spinal cord dorsal horn and major 
classes of different cells: excitatory, inhibitory neurons as well as glia cells like astrocytes and 
microglia. Under chronic pain conditions, excitatory neurons already showed to have 
increased Ca2+ signalling.  
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Hypothesis 
We hypothesise in this thesis that Ca2+ signals can be evoked by fibre stimulation from 
the dorsal root in different cell types of the spinal dorsal horn and that the Ca2+ 
signalling in astrocytes will change under different chronic pain conditions. In this 
context, we investigated the Ca2+ signalling behaviour of different cell compartments 
of astrocytes in acute spinal cord slices of mice under chronic inflammatory pain and 
neuropathic pain. 
We further hypothesise that Ca2+ signals in parvalbumin-positive neurons change 
under chronic pain conditions. As a consequence of this, we think that Ca2+ signalling-
dependent expression of genes like Npas4 then plays a crucial role in the development 
of chronic pain conditions and that its changes have an input on the development of 
chronic pain. 
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2 Materials and Methods: 
 
2.1 Molecular biological methods 
Plasmids and cloning plans of used constructs in this project were kindly provided by 
colleagues from the department Neurobiology, Heidelberg University, Heidelberg 
Germany. 
2.1.1 rAAV production 
For this study we used recombinant serotype 1/2 adeno-associated viral vectors 
(rAAV). In order to express in astrocytes different calcium indicators for calcium 
imaging, the rAAV included a plasmid with a human GFAP promotor (Brenner et al. 
1994) to control the green fluorescent GCaMP based genetically-encoded calcium 
indicators (GECIs) which were targeted to the cytoplasm (GCaMP5E), the plasma 
membrane (Lck.GCaMP5E) (Tang et al. 2015) and the nucleus (GCaMP3.NLS) 
(Bengtson et al. 2010). For the CRE-mouse line to target parvalbumin positive cells, 
which was kindly provided from the working group of Prof. Dr. Rohini Kuner, the 
created rAAV included a floxed EF1a:GCaMP5NES for the cytoplasm expression. For 
the CRE-mouse line to target astrocytes under Aldh1l1 promoter, we created and used 
rAAV with a EF1a:GCamP3.NLS expressing plasmid.  
For the behaviour experiments the rAAV constructs were supposed to increase or 
decrease the expression of NPAS4. To increase the basal NPAS4 expression we used 
an over expression plasmid under the human Synapsin promoter coupled to an HA-
tag and a tDimer for fluorescent expression (hSyn:Npas4.HA_hSyn:tdimer) and its 
control construct (hSyn:MCS.HA_hSyn:tDimer). To decrease the basal expression 
and also the induced expression of Npas4, we used a sh-binding function under the 
U6 promoter and GFP under CMV enhancer, chicken beta-Actin (CAG) promoter, for 
green fluorescent expression (U6:shNpas4_CAG:GFP) and its control which 
consisted of a scrambled version for the sh-construct (U6:shUNC_CAG:GFP) or the 
dominant negative construct which consisted of a sequence that would bind to the 
functional expressed protein and would therefore block its function 
(hSyn:dnNpas4.HA_hSyn.tDimer) and the control construct from the overexpression 
(see above).  
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For the production of the virus particles, carrying the announced constructs, HEK cells 
were grown in complete Dublbecco’s Modified eagle Medium (DMEM, Life 
Technologies Limited, Paisley, UK) (Table 1) on 14 cm plates and incubated at 37°C, 
95 % relative humidity and 5 % CO2. Two to three hours prior to virus transfection the 
medium from the HEK cells was completely changed to complete Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life Technologies Limited, Paisley, UK) (Table 2). The 
plasmids were mixed in a concentration of 65 µg with 1 M CaCl2 and sterile H2O and 
helper plasmids for viral capsid expression (125 µg pFD6, 31.25 µg pRV1 and 31.25 
µg pH21) and finally filter sterilized. Filter sterilized 2xHEBS with a pH of 8.0 (Table 3) 
was added and the solution was vortexed for 15 s. The substrate rested for more than 
90 s, building a fine participitate and then 5 ml per plate from the mix was added 
dropwise to the prepared HEK cell plates with a growth confluency of about 70-75 %. 
During this procedure the plate had to be swirled gently. 16-20 h post to transfection 
the medium was changed to fresh and pre-warmed (37°C) complete DMEM. 60-65 h 
post-transfection the medium was taken from the HEK cells, the cells were washed 
with pre-warmed (37°C) 1x PBS and harvested in 25 ml pre-warmed 1x PBS. The cell 
suspension was centrifuged at 2100 rpm for 5 min, supernatant discarded and the 
cells re-suspended in pre-warmed and filter sterilized NaCl (150 mM)/ Tris (20 mM) 
and frozen at -20°C. At least 24 h later the cell suspension was thawed at RT in a 
water-bath, then fresh sodium deoxycholate (Sigma, 10 % in sterile H2O) for a final 
concentration of 0.5 % and 5.1 µl Benzonase DNAse (Sigma-Aldrich Chemie GmbH, 
Munich, Germany) for final concentration of 50 U/ml were added, mixed thoroughly 
and incubated at 37°C in a water-bath for 1 h and mixed from time to time. Then the 
cell suspension was frozen at -20°C again for at least 24 h. Finally the virus was 
purified from the cells by thawing, centrifuging and loading the supernatant onto 
Heparin columns (HiTrap Heparin HP, GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden). Loading was followed by washing and then elution with increasing salt 
concentrations of NaCl/Tris (100 mM, 200 mM and 300 mM for washing, 400 mM, 450 
mM and 500 mM for elution). The virus solution was finally filtered and concentrated 
(Amicon Ultra – 4, Darmstadt, Germany) and washed with 1x sterile PBS. To confirm 
and evaluate the success of the virus production two experiments were done 
afterwards: SDS gel (Table 11) analysis to detect rAAV capsid proteins and extraction 
of viral DNA to determine the titre. For the capsid protein detection, 5 µl of the virus 
sample were taken and mixed with 15 µl 2x sample buffer with 1:1000 DTT and 
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incubated for 5 min at 95°C. The probes were then run on a 10 % SDS gel at 30 mA 
for ~1.5 h. Afterwards, the gel was stained with coomassie for 30 min at RT on a rocker 
and destained o/n at 4°C on a rocker with a paper towel tissue to take up the blue 
colour from the coomassie. For the records a photo was taken from the gel showing a 
successful virus production. 
For extraction of viral DNA, 2 µl of the viral stock is mixed with 10 µl of 10x ABI buffer 
(Table 4), 86 µl sterile H2O and 1 µl DNAseI to digest all remaining non-viral DNA. 
This mix was incubated for 30 min at 37°C in a water bath and the DNAseI was then 
inactivated by incubation at 70°C for 10 min. To digest the viral capsid, 1 µl proteinase 
K was added and incubated for 1 h at 50°C and finally inactivated at 95°C for 20 min. 
1 µl of each single-stranded viral DNA was then used for PCR reaction prepared with 
10 µM sense and 10 µM antisense primer, SYBR Green PCR master mix (2x) 
(ThermoFischer Scientific) as well as RNAse-, DNAse-free H2O. The probes were 
pipetted on a 96-well-plate, together with standards from 104-109 plasmid DNA 
molecules/µl and a negative control only consisting additional H2O. The PCR program 
was run with a thermal cycler C1000TM (Bio-Rad, Hercules, USA) (Table 13) and the 
mean quantity was taken to determine the viral titre. 
 
Table 1: Complete DMEM 
Name Stock 
concentration 
Final 
concentration 
Weight or Volume 
DMEM1   500 ml 
Heat-inactivated FBS1 
(Fetal Bovine Serum) 
  50 ml 
Non-essential amino 
acids (NEAA)1 
100x 1x 5 ml 
Sodium pyruvate2 100x 1x 5 ml 
Penicillin/Streptomycin2 200x 1x 2.5 ml 
1Life Technologies Limited, Paisley, UK 
2Sigma-Aldrich Chemie GmbH, Munich, Germany 
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Table 2: Complete IMDM 
Name Weight or Volume 
IMDM1 500 ml 
Heat-inactivated FBS1 25 ml 
1Life Technologies Limited, Paisley, UK 
 
 
Table 3: HEBS 2x 
Name Stock concentration Final concentration Weight or Volume 
HEPES 1 M 50 mM 25 ml 
NaCl 5 M 280 mM 28 ml 
Na2HPO4 1 M 1.5 mM 750 µl 
NaOH 1 M 1M  
ddH2O   (up to) 500 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
 
 
Table 4: 10x ABI 
Name Stock 
concentration 
Final 
concentration 
Weight or Volume 
KCl 3 M 0.5 M 3.33 ml 
Tris-HCl, pH 
8.0 
1 M 0.1 M 2.0 ml 
MgCl2 1.9 M 50 mM 526 µl 
ddH2O   (up to) 20 ml 
All chemicals are from sigma-Aldrich Chemie GmbH, Munich, Germany. 
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2.1.2 Primary hippocampal cell culture 
For testing if the constructs were efficient in expression and their function, the different 
viruses were tested in vitro before injecting them into mice. The cells were freshly 
prepared hippocampal primary cultures either with or without glass coverslips.  The 
culture dishes were coated with 200 µl Poly-D-Lysin (PDL)/ 90 µl Laminin mix in 15 ml 
H2O  (Sigma-Aldrich Chemie GmbH, Munich, Germany) O/N in the cell culture 
incubator and washed with sterile H2O 24 h later and prepared with L-glitamine 
neurobasal medium (gibco life Technologies, Thermo Fisher Scientific, MA, USA). The 
cells were kept in an incubator with 37°C and 95 % relative humidity and 5 % CO2. At 
DIV 3 the culture was treated with 1:1000 cytosine arabinoside (AraC) in the morning 
to reduce the amount and growth of glia cells and infected with the previously prepared 
viral constructs in the evening. The medium was changed completely to transfection 
medium (TM) (Table 10) on DIV 8. The treatment with BIC or without BIC as control 
for 2 h, to determine the activity and the function of the tested virus, was done on DIV 
10. The cells were then ready for harvesting to check for protein levels, mRNA 
expression or to mount the coverslips with primary infected neurons with 
Hoechst/Mowiol to make example pictures of the expression in the cells due to the 
construct. 
 
2.1.3 Primary spinal cord culture 
As we wanted to test the constructs in mouse spinal cord, we also considered testing 
several constructs in spinal cord cell culture. For that, the pups that were sacrificed for 
hippocampal cell culture, were after beheading taken for spinal cord isolation. After 
isolation, the dura mater was removed from spinal cord tissue and the spinal cord 
tissue was cropped into two to three pieces. The tissue was then transferred into 
enzyme solution (Ky/Mg in dissociation medium + 22.5 mg L-cysteine, Sigma-Aldrich 
Chemie GmbH, Munich, Germany + 500 units papain, CellSystems GmbH, St. 
Katharinen, Germany) (Table 6-7), incubated for 20 min at 37°C in a water bath with 
a magnetic fish to slowly but continuously swirl the solution and in addition carefully 
swirled by hand every 5 min. Then the solution was carefully removed and the step 
was repeated. Afterwards, the tissue was washed three times for 1 min each with 2 ml 
dissociation medium and then incubated two times for 5 min each in inhibitory solution 
(Ky/Mg in dissociation medium + 1 g trypsin inhibitor, Sigma-Aldrich Chemie GmbH 
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Munich, Germany + 0.2 M NaOH) (Table 6 -7) at 37°C in a water bath. The tissue was 
washed three times for 1 min with 2 ml NBA/growth medium (Table 8) and then 
dissociated 50 times by pipetting up and down in 2 ml NBA medium and the cell 
suspension was then allowed to rest for 5 min. The suspension was carefully removed 
and transferred to a 15 ml falcon tube. This step was repeated three times. In the end 
a total cell suspension volume of ~ 10 ml was determined for its cell concentration and 
calculated for different diameters of culture dishes (Table 5). 
 
Table 5: Cell distribution according to plate. 
Plate ~ Area 
(cm2) 
Cells Volume (with 0.5 x 106 cells/ml) 
35 mm 9.6 1 x 106 2 ml 
6-well 9.6 1 x 106 2 ml 
12-well 3.8 0.75 x 106 1 ml (1.5 ml 2.5 h medium change) 
24-well 1.9 0.25 x 106 0.5 ml (1.5 ml 2.5 h medium change) 
4-well 1.9 0.25 x 106 0.5 ml (1 ml 2.5 h medium change) 
48-well 0.95 0.125 x 106 0.25 ml (0.5 ml 2.5 h medium change) 
 
2.5 h after cells were pipetted into culture dishes, the medium was changed to fresh 
NBA. Cells were checked upon every day. AraC treatment was done at DIV 4 in the 
morning, viral transfection in the evening. Medium change to transfection medium ™ 
(Table 9-10) was done at DIV 8 or 9, experiment was done at DIV 10 or 11. 
 
Table 6: Ky/mg solution. 
Component Final concentration Stock concentration For 80 ml 
Kynurenic acid 10 mM Powder 158.56 g 
MgCl2 100 mM 2 M 4 ml 
HEPES 5 mM 1 M 0.4 ml 
Phenol red 0.5 % v/v 100 % 0.4 ml 
NaOH 12.5 mM 1 M 1 ml 
H2O   up to 80 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
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Table 7: Dissociation Medium (DM). 
Component Final concentration Stock concentration For 80 ml 
Na2SO4 81.1 mM 1 M 20.45 ml 
MgCl2 5.85 mM 1.9 M 0.77 ml 
K2SO4 30 mM 0.25 M 30 ml 
CaCl2 0.25 mM 1 M 0.063 ml 
HEPES 1 mM 1 M 0.25 ml 
Glucose 20 mM 2.5 M 2 ml 
Phenole red 0.2 % v/v 100 % 0.5 ml 
H2O   up to 250 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
 
 
Table 8: NB-A/Growth Medium (GM). 
Component For 100 ml 
Neurobasal A-medium 97 ml 
B 27 2 ml 
Rat serum 1 ml 
Glutamin (200 mM) 0.25 ml 
Penicillin/Strepomycin 0.5 ml 
H2O Up to 100 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Sterile filtered through 0.22 m Millipore filter and stored at + 4°C. 
 
 
Table 9: Salt Glucose Glycine Solution (SGG). 
Component Final concentration Stock concentration For 80 ml 
NaCl 114 mM 5 M 11.4 ml 
NaHCO3 0.22 % v/V 7.5 % m/v 14.6 ml 
KCl 5.29 mM 3 M 0.882 ml 
MgCl2 1 mM 1.9 M 0.264 ml 
CaCl2 2 mM 1 M 1 ml 
HEPES 10 mM 1 M 5 ml 
Glycine 1 mM 1 M 0.5 ml 
Glucose 0.54 % v/v 45 % m/v 6 ml 
Sodium pyruvate 0.5 mM 0.1 M 2.5 ml 
Phenole red 0.2 % v/v 100 % 0.5 ml 
H2O   up to 500 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Sterile filtered through 0.22 m Millipore filter and stored at + 4°C. 
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Table 10: Transfection Medium (TM). 
Component For 100 ml 
SGG 88 ml 
MEM (without glutamine) 10 ml 
ITS 1.5 ml 
Penicillin/Strepomycin 0.5 ml 
H2O Up to 100 ml 
All chemicals are from Sigma-Aldrich Chemie GmbH, Munich, Germany. 
Sterile filtered through 0.22 m Millipore filter and stored at + 4°C. 
 
 
2.1.4 Protein expression (SDS Page) 
For examination of the targeted protein levels in the cell culture with or without BIC 
treatment, the cells were cultured in 35mm dishes and treated as described above. At 
DIV 10 the cells were harvested with 2xsample buffer (30 % glycerol, 4 % SDS, 169 
mM Tris-HCl 1 M pH 6.8, 0.02 % bromophenol blue, ddH2O) with 1:1000 DTT and 
incubated at 95°C for 5 min on a heating block to break the sulfate bridges between 
the proteins in order to unfold them for a separation on a SDS gel. The samples were 
then loaded on a 10 % SDS gel, containing of a stacking gel and a separation gel 
(Table 11). After ~ 70 min at 30 mA the gel was taken out of the chamber to blot it onto 
a nitrocellulose membrane (Waterman) for 2h with constant voltage of 20 V 
(Transferring buffer: 150 mM glycine, 20 mM Tris, 0.1 % SDS and 20 % Methanol). 
The membrane was marked to not lose orientation and then stained with ponceau 
(SERVA Elecotrophoresis, Heidelberg, Germany) for 10-15 min on a rocker at RT to 
check the quality of the blot. When no bubbles were disturbing the blot, then the 
membrane was rinsed with H2O and blocked with 5% milk (frema Reform, Instant-
Magermilchpulver, Radolfzell, Germany) in Phosphate buffered saline with Tween-20 
(PBST) for 30 min, washed 3x10 min with PBST and then incubated in the first 
antibody (1:400 000 for α-Tubulin and 1:5000 for the other antibodies, see table X) in 
5 % milk PBST or 5 % BSA (albumin fraction V, Roth) in PBST (for Npas4 antibody) 
for 2 h at RT on a rocker or o/n at 4°C, washed with PBST 3x10 min and finally 
incubated on a rocker at RT with secondary antibodies in 5 % milk PBST for 30 min 
(Table 19) at RT. The membrane was washed with PBST and incubated for 5 min with 
ECL detection solution (Bio-Rad, Hercules, USA) and the pictures were taken with the 
ChemiDocTM imaging system (Bio-Rad, Hercules, USA). 
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Table 11: SDS-PAGE. 
Solution Stacking gel (3.7%) 10ml Seperation gel (10%) 
20ml 
H2O 6.25 ml 8.2 ml 
4x Buffer 1 2.5 ml 5 ml 
Rotiphorese Gel 30 2 1.25 ml 6.7 ml 
10% APSc 3 100 µl 100 µl 
TEMED 4 10 µl 10 µl 
1 4x stacking gel buffer: 0.5 M Tris-HCl, pH 6.8 and 0.4% (w/v) SDs; 
  4x separation gel buffer: 1.5 M Tris-HCl, pH 8.8 and 0.4% (w/v) SDS. 
2 30% Acrylamid solution with 0.8% Bisacrylamid from Carl Roth (Karlsruhe, 
Germany) 
3 10% (w/v) ammonium persulfate (APS) H2O. 
4 N,N,N’,N’-Tetramethyl-ethylenediamine from SERVA Electrophoresis 
(Heidelberg, Germany). 
 
 
2.1.5 Gene expression analysis 
2.1.5.1 cDNA synthesis 
All RNA related work was conducted under RNase-free conditions. The cells were 
collected with freshly prepared 1% β-Mercaptoethanol (ME) in lysis buffer (RLT) and 
scratched off the surface of the dishes (3.8 cm2 12-well plate, each with 300 µl RLT/ME 
mix). Additional 300 µl 70% ethanol was added and mixed well to be put onto a 
RNeasy Mini Kit column (Qiagen, Venlo, Netherlands) placed in a 2 ml collection tube 
and RNA was purified as described in their provided protocol, including the optional 
steps by using on-column DNaseI digestion (RNase-free DNase Set Qiagen). After 
elution concentration was measured and a master mix (Table 12) was prepared. For 
each sample, 6.3 µl of master mix was mixed with 1.0 µg of RNA to produce cDNA in 
a PCR reaction (Table 13).  
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Table 12: cDNA synthesis mixture. 
Solution1 Volume for total 20 µl 
(10x) RT buffer 2 µl 
(100 nM, 10x) dNTPs 0.8 µl 
(10x) Random primers 2 µl 
(50 U/µl) Reverse transcriptase 1 µl 
(40 U/µl) RNase inhibitor 0.5 µl 
RNase-free H2O 3.7 µl 
1 All chemicals are provided by Applied Biosystems, Waltham, USA. 
+ 20 µl diluted RNA (1.0 µg) for each reaction 
 
 
Table 13: cDNA synthesis program. 
Procedure step Temperature Duration 
1. Annealing 25°C 5 min 
2. Annealing/Elongation 37°C 120 min 
3. Denaturation 85°C 5 s 
4. Storage 4°C for ever 
PCR reaction was performed in thermal cycler C1000TM (Bio-Rad, Hercules, 
USA) 
 
 
2.1.5.2 Real-time quantitative PCR 
PCR product, cDNA, was then filled up with 100 µl sterile and RNAse and DNAse free 
H2O. For real-time (RT) quantitative (q) PCR, a master mix for each gene was 
prepared (Table 14-15) from TaqManR (Applied BiosystemsR, Waltham, USA). 5.5 µl 
of TaqMan master mix was mixed with 4.5 µl of cDNA and then run with a 
StepOnePlusR real time PCR system (Applied BiosystemsR) with a temperature 
program presented in table 16 to determine the expression levels of the targeted 
genes. Target mRNA expression level was normalized to the relative ratio of the 
expression of Gusb mRNA. 
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Table 14: RT-qPCR taqman probes. 
Acronym Gene name Assay ID 
Arc Activity regulated cytoskeletal-associated 
protein 
Mm00479619_g1 
Bdnf Brain derived neurotrophic factor Mm00432069_m1 
cFos FBJ osteosarcoma oncogene Mm00487425_m1 
Gusb Glucuronidase, beta Mm00446953_m1 
Inhba Inhibin beta-A Mm00434338_m1 
Npas4 Neuronal PAS domain protein 4 Mm00463644_m1 
Nptx2 Neuronal pentraxin 2 Mm00479438_m1 
All probes are designed by Applied BiosystemsR (Waltham, USA) 
 
 
Table 15: RT-qPCR reaction mix per well. 
Solution For 10 µl 
(2x) Master mix 5 µl 
(20x) Probes 0.5 µl 
(diluted) cDNA 4.5 µl 
 
 
Table 16: RT-qPCR temperature program. 
Procedure step Temperature Duration 
1 50°C 2 min 
2 95°C 10 min 
3 95°C 15 s 
4 60°C 1 min 
5 Go to step 3 50 cycles 
6 Stop For ever 
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2.2 Animal work 
This study was approved by the local animal care and use committee 
(Regierungspräsidium Karlsruhe, Referat 35, Karlsruhe, Germany), project G-272/14. 
All animal experiments were designed and carried out in accordance with ARRIVE 
guidelines and the EU Directive 2010/63/EU for animal experiments. 
 
2.2.1 Mouse lines 
Aldh1l1-Cre/ERT2 treatment with tamoxifen. The Cre/ERT2 toolbox is reduced in its 
cre activity in the absence of tamoxifen. To induce cre recombination, adult male mice 
that were injected with EF1a:FLEX(GCaMP3.3xNLS.myc) rAAV received tamoxifen 
injection i.p. for five days, one week after viral injection. 
Parvalbumin CRE-mouse line was used for specific viral transported Ca2+ indicators 
in parvalbumin positive cells in the spinal cord of the mice. 
For most of the studies, either for astrocyte Ca2+ imaging analysis or for investigation 
of the early immediate gene Npas4, C57BL/6N wild-type mice (Charles River, Sulzfeld, 
Germany) were used for the experiments. 
Mice were either housed in the facility of Heidelberg University (Interfakultäre 
Biomedizinische Forschungseinrichtung (IBF)), the behavioural facility 
Interdisciplinary Neurobehavioral Core (INBC, Heidelberg Universit) or the 
neurobiology department (Heidelberg University, Germany). Mice were group-housed 
on a 12 h light/dark cycle with ad libidum access to water and food. Surgeries and 
behavioural tests were performed during light phases. Behavioural tests were 
performed in the morning hours. 
 
2.2.2 Virus injection 
In order to express the different rAAVs, the virus construct was injected into the mice 
spinal cord. The virus was prepared in a dilution 2:1 with Manitol or undiluted and filled 
into a 1ml Hamilton needle. Sleep mix (table) was prepared freshly and injected IP (1 
g = 10 µl) according to the weight of the mouse. Mice’s backs were shaved above the 
spinal cord, the back was disinfected and to protect the eyes from drying out during 
the surgery, some salve (Bepanthen, Bayer) was put on the mice eyes, then Carprofen 
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(table) (1 g = 10 µl) as analgesia was injected sub-cutaneously in order to prevent the 
mouse from suffering post-surgery pain. The mouse was placed down on a warming 
plate (39°C) and the back was supposed to be slightly bent into a hunchback to identify 
L3-L5 position of the spinal cord. Skin and muscles were opened carefully. Spinal cord 
was revealed and the dura opened. As soon as the needle (35 G bevelled needle 
(WPI; NANOFIL, NF35BV) was in place to be inserted into spinal cord tissue, left or 
right of the dorsal blood vessel, it was tested if it was clogged or if viral solution would 
come out as mannitol tends to build crystals at RT. When the needle was not clogged, 
it was inserted into spinal cord tissue until the opening of the needle was not visible 
anymore. Before injection, the needle had to rest in position for 5 min then injection 
started: 500 nl / injection, speed: 50 nl / min. In addition the injected liquid was allowed 
to distribute in the tissue for another 5 min before removing the needle from the spinal 
cord dorsal horn. To close the wound a piece of gelatine sponge was put directly onto 
the open wound and the cut was closed with 3:1:2 stiches. For local anaesthesia 
lidocaine (Aspen Pharma Trading Limited, Dublin, Ireland) was sprayed directly onto 
the closed wound. Wake-mix was injected sub-cutaneously and after awaken the 
mouse was tested for hind-limp function to exclude any possible damage due to 
surgery. To prevent post-surgical pain, 1 h after wake-mix application, Buprenorphine 
was injected. Mice were kept on a warming plate (39°C) O/N to recover from surgery 
and got wet and soft food pellets.  
 
Table 17: Mice injection solutions. 
Mix Company Component and amount Concentration 
Sleep Mix 
(for 1 ml) 
 0.9% NaCl 750µl  
Sedin Medetomidinhydrochlorid 
50µl 
stock: 1 mg/ml 
Midazola
m-hameln 
Midazolamhydrochlorid 
100µl 
stock: 5 mg/ml 
Fentanyl-
Piramal, 
Critical 
Care 
Fentanylcitrat 100µl stock: 0.05 mg/ml 
Carprofen 
Analgesia 
(for 5 ml) 
 0.9% NaCl 4.95ml  
Carprieve, 
Norbrook 
Carprofen 50µl stock: 50 mg/ml 
 0.9% NaCl 750µl  
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Wake Mix 
(for 5 ml) 
Atipazole Atipamezolehydrochlorid 
250µl 
stock: 5 mg/ml 
 Flumazenil Kabi 
Fresenius 
Flumazenil 2.5ml stock: 
0.1 
mg/ml 
Naloxon Inresa Naloxonhydrochlor
id 1.5ml 
stock: 
0.4 
mg/ml 
Buprenorphi
ne Analgesia 
(for 5 ml) 
 0.9% NaCl 4.88ml  
 Buprenorphine 120µl stock: 0.324 mg/ml 
 
2.2.3 Acute spinal cord slices 
Three weeks after virus injection and after treatment with one of the pain protocols 
(see below) the mouse was prepared for acute slicing. Needed solutions (Table 18) 
were prepared and slicing solution was cooled down to ~4°C. Mice were injected with 
Narcoren and as soon as they were not responding to foot pinches, the thorax was 
opened and perfused with ice cold carboxylated slicing solution. Spinal cord was then 
taken out and dura removed from the spinal cord. The spinal cord with dorsal roots 
attached to the infected hemisphere was then mounted into a groove within a block of 
1.5 % agarose in PBS and secured with cyanoacrylate adhesive to the stage of a 
Microm HM650V (Thermo Scientific) vibratome containing NMDG slicing solution 
bubbled with 95 % O2/5 % CO2 and cooled to 1-4 °C. Slices (~330 µm) were prepared 
using double edge coated blades (Science Services, washed version, #7200-WA) and 
then placed into NMDG slicing solution bubbled with 95 % O2/5 % CO2 and warmed 
to 34 °C for ten minutes. Slices were subsequently transferred to extracellular 
recording solution (Table 18) adjusted to a final osmolarity of 300-305 mOsm and pH 
7.35, bubbled with 95 % O2/5 % CO2 and warmed to 34 °C, and then allowed to cool 
to room temperature for a recovery period of ≥ 1 hour 
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Table 18: Slicing and imaging solutions. 
 Name Stock MW or 
concentration 
Final 
concentration 
Weight 
or 
Volume 
NMDG/HEPES slicing 
solution (500 ml, pH 7.35, 
final osmolarity: 300-305 
mOsm) 
Fresh on the day of use! 
NMDG (N-
methyl-D-
glucamine)  
195.22 
g/mol  
93 mM  
9.07773 
g  
HCl  37 %  93 mM  ~3.2 ml  
KCl  3 M  2.5 mM  416.7 µl  
NaH2PO4  1 M  1.2 mM  600 µl  
sodium 
pyruvate  
500 mM  3 mM  3 ml  
HEPES  1 M  20 mM  10 ml  
NaHCO3  1 M  30 mM  15 ml  
D-glucose  1.25 M  25 mM  10 ml  
L+ ascorbic 
acid  
176.12 
g/mol  
5 mM  
0.4403 
g  
N-acetyl-L-
cysteine  
163.19 
g/mol  
10 mM  
0.81595 
g  
thiourea  76.12 g/mol  2 mM  
0.07612 
g  
MgSO4  2 M  10 mM  2.5 ml  
CaCl2  2 M  0.5 mM  125 µl  
ddH2O   (up to) 
500 ml 
Recording solution (2l, pH 
7.35, final osmolarity: 
300-305 mOsm) 
Storage at 4°C 
NaCl  58.4 g/mol  125 mM  14.6 g  
D-glucose  
180.16 
g/mol  
10 mM  3.6 g  
NaHCO3  84.01 g/mol  25 mM  4.2 g  
KCl  3 M  2.5 mM  1.67 ml  
NaH2PO4  1 M  1.25 mM  2.5 ml  
MgSO4  2 M  1.2 mM  1.2 ml  
CaCl2  2 M  2.0 mM  2.0 ml  
ddH2O      
(up to) 2 
l  
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2.2.4 In vivo imaging and recording 
Single spinal cord acute slices were placed to a recording chamber (PM-1, Warner 
Instruments, Hamden, CT, USA or PC-R, Siskiyou, OR, USA) perfused (~3 ml/min) 
with 95 % O2/5 % CO2-bubbled extracellular recording solution warmed with an in-
line heater to 34 °C. The slices were secured with a platinum harp ring with nylon 
strings. Dorsal roots were sucked into a glass stimulation electrode, the tip of which 
had been dipped into Vaseline to improve the electrical seal around the root. We 
regularly controlled the electrode resistance to ensure that it was greater than 20 kθ. 
The stimulation was controlled by a stimulus isolator (World Precision Instruments, 
A365) controlled by Clampex10.3 Software (Molecular Devices) or a stimulus isolator 
(STG 4002, Multichannel Systems) controlled by MC Stimulus II software 
(Multichannel Systems) (Fig. 5 D). 
Figure 5: Experimental procedure rAAV injection, pain protocols and stimulation of acute 
slices. (A) Schematic drawing of rAAV introducing Ca2+ indicator into mice spinal cord dorsal 
horn. (B) Two different pain models: 1. Neuropathic pain model with SNI or sham surgery 3 
weeks after rAAV injection and performance of acute slicing and Ca2+ imaging at day 28 (7 days 
after SNI/sham surgery). (C) Example picture of acute slice under imaging set-up and suction of 
dorsal root. In the dorsal root there are periphery fibres represented like Aβ-, Aδ- and C-fibres, 
forming synapses in the spinal dorsal horn. (D) Stimulation protocol for the preferred fibre 
classes, their stimulation frequency, pulse duration and train duration of the single stimulations. 
Stimulation intensities started at 0.01 mA followed by 0.05, 0.1, 0.2, 0.5, 0.8 and finally 1 mA. 
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At the end of the stimulation protocol, the slice was exposed to a high concentration 
of potassium to cause a strong increase in intracellular Ca2+. GCaMP constructs were 
excited using a CooLed light source (480±10 nm), and fluorescence emission (530±20 
nm) acquired at a rate of 2 Hz with a cooled camera (Photometrics Coolsnap HQ, 
Roper Scientific) with 2x2 binning through a 20x water-immersion objective (XLM 
PlanFluor 0.95W, Olympus) on an upright microscope (Olympus BX51WI) connected 
through a software interface (Metafluor, Universal Imaging Systems and Molecular 
Devices). Overview images were taken with a 4x air objective (PlanCN, Olympus). 
After recording, the electrode was removed from the dorsal root and the slice was 
stored for further immunohistochemistry analysis in 4% formalin for ~2 h and then 
stored in 30% sucrose at 4°C for cryo-protection. 
 
2.2.5 Cryo slices 
Whole spinal cords or fixed former acute slices were used for cryo slicing for further 
immunohistochemistry staining. For whole spinal cord slicing, Narcoren injected mice 
were perfused with PBS first and then with 4% formalin on ice. Spinal cord was 
extracted and post-fixed in 4% formalin for additional 2 h and afterwards incubated in 
30% sucrose at 4°C at least O/N. Fixed spinal cord with placed in cryo-cutting medium 
and then placed anterior side down on a cryostat holder and slicing was performed at 
a Leica-Cm1950 cryostat. Spinal cord or spinal cord slices were cut at -15°C into 20 
µm and secured on superfrost coated glass slides. For storage the slides were kept in 
a cryo box at -20°C. 
 
2.2.6 Fresh tissue harvest 
To determine the amount of certain gene or protein expression in vivo, fresh spinal 
cord tissue was taken of narcotised beheaded mice. The tissue was rinsed in cold 1x 
PBS, shock frozen with dry ice pieces and the dorsal horn from the area L3-L5 was 
separated from the rest of the spinal cord. Tissue was then incubated and 
homogenised in RIPA buffer (5 M NaCL, 1 % Triton X-100, 0.5 % sodium 
deoxycholate, 0.1 % SDS, 50 mM Tris 1 M pH 8.0, ddH2O) with protein inhibitor. For 
protein concentration measurement, BCA Kit was used after centrifugation of the 
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probes. Probes were then used for gene expression (PCR & qPCR) or protein 
expression (SDS Page), see methods above. 
 
2.2.7 Immunohistochemistry and immunocytochemistry 
To stain the spinal cord cryo slices they were dried at 50°C for 20 mins. With a pap-
pen a circle was drawn around the slices and they were incubated for 1 h 30 mins with 
GDB 2x + 10 % normal goat serum (NGS) or normal donkey serum (NDS), depending 
on the host of the secondary antibody. The blocking solution was removed and the 
slices were washed three times for 10 min with 1% Triton X-100 in 1 x PBS. Then 
slices were incubated with the first antibody at RT O/N in a moist chamber to prevent 
the slices to dry out O/N. Next day the first antibody was removed and slices were 
washed again as mentioned before. Then the slices were incubated for 1 h 30 min at 
RT with the secondary antibody in GDB 2x + 10% serum medium. After incubation the 
slices were washed like described above and then optionally treated with 0.01% 
Sudan Black B in 70% ethanol for 15 min to reduce background binding from 
antibodies and then washed again as indicated. Finally the slices were mounted by 
addition of a mix of Hoechst in Mowiol (1:5000) and covering with a glass coverslip.  
 
Table 19: List of antibodies. 
1. Antibody Host species Company Dilution 
GFAP (clone G5) mouse IgG1 Cell Signaling 
Technologie, 3670 
1:300 
GFP rabbit polyclonal Molecular Probes, A-
6455 
1:300 - 1:500 
NeuN mouse clone A60 Millipore, Merck, 
MAB377 
1:1000 
Npas4 rabbit monoclonal ActivitySignaling.com 1:5000 
Alpha Tubulin mouse monoclonal Sigma, 9026 1:400000 
Isolectin B4 Biotin-conjugate Sigma, L2140 1:250 
HA.11 mouse 16B12 IgG1 BioLegend, MMS-
101R 
1:5000 
2. Antibodies   Concentration 
Alexa 594 goat anti mouse Invitrogen, A11005 1:500 - 1:1000 
Alexa 488 goat anti rabbit Invitrogen, A11008 1:500 - 1:1000 
Alexa 594 donkey anti rabbit Dianova, 711-585-152 1:500 
Mouse goat IgG, HRP DIanova 115-035-003 1:5000 
Rabbit goat IgG, HRP Dianova, 115-035-144 1:5000 
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Pictures from the fixed and stained slices were made with a wide field microscope 
(Leica DM IRBE, camera: Monochrome w/o IP, Diagnostic instruments, inc., USA, 
software: Visiview, Visitron Systems, Puchheim, Germany). 
 
2.3 Animal pain model – protocols and behavioural tests 
2.3.1 Complete Freund’s Adjuvant (CFA) 
For chronic inflammatory pain we used CFA (Sigma F5881-10ml, St. Louis, MO, USA) 
which is a heat killed Mycobacterium tuberculosis (strain H37Ra, ATCC 25177) which 
attracts macrophages and thus causes inflammatory chronic pain. Mice were 
anaesthetized with Isofulrane in CO2 (5% at the start and during injection at 2%, EZ-
Anesthesia EZ 702). 20 µl of CFA was injected under the skin, parallel to the surface, 
on the ventral side of the left hind paw of the animal, directly behind the walking pads. 
The injection needle had to be inside the paw for 1 min to let the CFA distribute inside 
the tissue. After rejecting the needle, the mouse was released from the Isoflurane and 
woke up after 30s – 1min and was then placed back into its home-cage. Animals for 
Ca2+ imaging were tested 24 h after injection. Mice which were included into pain 
behaviour von Frey and Hargreaves testing (see below) were tested 6 h, 24 h, 72 h, 5 
d, 7 d and 10 d after injection.  
 
2.3.2 Spared Nerve Injury (SNI) 
One common used neuropathic chronic pain model is SNI surgery (Decosterd and 
Woolf 2000). Mice were anesthetized with an IP injection of sleep mix (10µl/g, see 
table 17). As soon as mice were asleep, the skin and the muscle from the left hind 
limb was opened to get access to the peroneal, tibial and sural nerve. The common 
peroneal nerve, the tibial nerve and the sural nerve were carefully freed from muscle. 
Then common peroneal and tibial nerve were ligated by a sural branch, whereas the 
sural nerve must stay intact and unharmed. About 1 mm of the ligated nerve was cut 
away after ligation to ensure that the endings of the separated nerves would not 
recover by ligating to their cut-off ends. Muscles were carefully placed back into 
position to cover the nerves. This surgery triggers neuropathic hypersensitivity. After 
the cut was closed, wake mix was injected subcutaneously and lidocaine spray was 
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applied to decrease post-surgical stress for the animals. The mouse was put back into 
its cage with wet food pellets and the cage was placed onto a heating plate o/n for the 
mouse to recover. After 7days the mouse was sacrificed for the final experiment. 
 
2.3.3 Pain behaviour 
Observers were blinded to the identity of the animal groups in all behavioural tests. 
 
2.3.3.1 Catwalk 
Mice were analysed for their locomotor and walk behaviour before spinal cord 
injection, before and after chronic pain induction, by testing in a catwalk (CatWalkXT, 
Noldus). Mice were habituated to the catwalk in the dark for 10-15 min 24h before 
testing. While testing, three runs were taken where the mice were continuously running 
and not stopping during recording to generate an average of walk behaviour. Animals 
were not habituated again to the catwalk when tested in it at later time point. Mice that 
showed impaired walking behaviour after spinal cord injections, for example limping, 
were excluded from further experiments. 
 
2.3.3.2 Mechanical sensitivity (von Frey test) 
Animals were acclimatized to the experiment room and the test boxes 3-4 days prior 
to experiments and baseline measurements were taken 2 days before pain protocol 
application. Mice were then placed on an elevated wire grid and mechanical sensitivity 
determined upon paw withdrawal to either application of graded force via a dynamic 
aethesiometer (Ugo Basile Inc.) or to manual application of graded von Frey hairs 
(0.07 – 4 g) to the plantar surface. Response frequency was calculated as the mean 
number of withdrawals out of five applications of the respective filament in 2-4 min 
intervals. Withdrawal threshold was determined as the filament at which the animal 
withdraws its paw at least two times out of five applications (40% threshold) or three 
times out of five applications (60% threshold). 
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2.3.3.3 Thermal sensitivity (Hargreaves test)  
All experiments for von Frey and Hargreaves tests were obtained in the 
Interdisciplinary Neurobehavioral Core (INBC), Heidelberg, Germany. 
Paw withdrawal latency to a ramp of infrared heat was measured using a plantar test 
apparatus (Ugo Basile Inc.). Animals were acclimatized to the experiment room and 
experiment boxes for 3-4 days and baseline measurement was taken 2 days before 
pain protocol application. Light was pointed to the left hind paw five times in 2-5 min 
intervals. Measurements were only valid when the mice were not busy with grooming 
or exploring their environment. Time was measured from the starting of the light 
application until withdraw of the hind paw. Withdrawal threshold was determined as 
mean of the withdrawal times in one session. 
 
2.3.3.4 Cold plate 
Animals were tested for cold hypersensitivity before spinal cord injection, after spinal 
cord injection and after pain protocol induction. Testing was always done directly after 
von Frey testing. The cold plate (Ugo Basile Inc.) was cooled down to 4°C and mice 
were tested one by one by placing on the plate and time was recorded until the first 
reaction, like paw lifting, licking or shaking. 
After experiments, the animals were placed back into their home cages. 
 
2.4 Data Analysis 
Graphs for this thesis were made with Prism (GraphPad Software, La Jolla, USA, 
version 6.0). Images were processed with Adobe Photoshop (Adobe Systems Inc., 
San Jose, USA, version 2015) or ImageJ. All graphs were finalised with Power Point 
(Microsoft Corporation, Redmond, WA, USA) or Adobe Illustrator (Adobe Systems 
Inc., San Jose, USA, version 2015). All references were managed through Endnote 
(Clarivate Analytics, Phildadelphia, USA, version X8). Statistical analysis for graphs 
was done as well with Prism. All figures presented in the result section include the 
used statistical tests in their legends. For most of the tests one-way ANOVA for 
multiple comparison was used. In general, the following definition for significance was 
made: not significant (n.s.): p > 0.05; *: p < 0.05; **: p < 0.005; ***: p < 0.001. 
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3. Results 
 
3.1 Ca2+ indicator-injection into the mouse spinal cord dorsal horn 
In previous studies it was shown that Ca2+ signalling in spinal dorsal horn excitatory 
neurons plays a role in the development and maintenance of chronic pain conditions 
Figure 6: Verification of spinal cord dorsal horn injections. GFAP:GCaMP3NLS.myc 
Ca2+ indicator expression in spinal cord dorsal horn laminae I-III. (A) and (B) showing 
immunohistochemistry staining of fixed slices expressing Ca2+ indicator (GFP in green) and 
Isolectin B4 expression (red) on fibres membrane. Scale bar = (A) 200 µm and (B) 100 µm. 
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(Simonetti et al. 2013) as it is necessary for signal transmission from in the responsible 
circuits. In addition nuclear Ca2+ signalling induces gene transcription which is 
necessary to lead to structural and functional changes of the neuron. However, many 
questions remain unsolved and our knowledge about the involvement of Ca2+ signals 
and its possible changes in chronic pain conditions or its role in the actual development 
of chronic pain are limited.  
In order to investigate the role of Ca2+ signalling in different cell compartments of 
different cell types in the spinal dorsal horn, Ca2+ indicators were injected for analysis 
of acute slices under dorsal root stimulation.  
To first verify the injection method and quality, wild-type mice were injected with a Ca2+ 
indicator which is located in the nucleus of astrocytes (GFAP:GCaMP3NLS.myc). 
Further results on this Ca2+ indicator will be presented in section 3.1.1.3 Nuclear Ca2+ 
signalling in GFAP-positive cells. After 2-3 weeks of incubation time for expression of 
the indicator, the mice were sacrificed and perfused with 4 % PFA. Following the 
extraction of the spinal cord, the tissue was post fixed for another 1 h in 4 % PFA and 
cryo-preserved in 30 % sucrose. Then the spinal cord was cut at the cryostat into 20 
µm thick slices and probed with a GFP antibody and for visualisation with Alexa 488 
in order to amplify the GFP signal from the Ca2+ indicator and Isolectin B4-594 for 
marking the superficial lamina of the dorsal horn.  Isolectin B4 is one common way to 
label unmyelinated and small diameter (thus C-fibers) sensory neurons as these 
afferent neurons from the periphery express on their membrane carbohydrates where 
the plant lectin isolectin B4 from Griffonia simplicifolia can bind to. The fluorescent 
pictures (Fig. 6) show that the GFP expressing indicators were close to the Isolectin 
B4 expressing cells in laminae I-III. Laminae I-III was the target area to investigate 
fibre induced Ca2+ signalling in the dorsal horn as a first contact side from the periphery 
to the CNS. GFP expression from inside the nucleus was visible in close proximity of 
Isolectin B4 positive signals. Further experiments were planned due to the 
confirmation of this experiment.  
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3.1.1 Ca2+ signalling behaviour in spinal cord dorsal horn astrocytes 
under chronic pain conditions 
It was shown that astrocytes react with astrogliosis under chronic pain conditions but 
still many aspects of astrocytes and especially their Ca2+ signalling in the spinal dorsal 
horn under chronic pain conditions remain unresolved and are poorly understood. 
Particularly the role of different astrocytic cell compartments and their role in Ca2+ 
signalling. Thus, the investigation and characterisation of dorsal root evoked Ca2+ 
signals in astrocytes also under chronic inflammatory pain and neuropathic pain were 
the first aim of this project. 
 
3.1.1.1 Cytoplasmic Ca2+ signalling in GFAP-positive cells 
It has already been shown that astrocytes can react with Ca2+ signals to stimuli like 
neurotransmitters from synaptic clefts. Right now, little is known about the role of Ca2+ 
signals in astrocytes in the dorsal horn under chronic pain conditions. Here, we used 
a Ca2+ indicator which expresses GFP when bound to Ca2+/calmodulin. This indicator 
is not able to enter the nucleus, as it is too big to cross the nuclear membrane through 
nuclear pore complexes. Hence, the indicator is located in the cytosol and mainly 
visible in the soma of the astrocytes due to the surface-to-volume ratio which is higher 
for the volume in the soma compared to the higher amount of surface of fine 
processes. In Fig. 7 A the used rAAV introduced construct for Ca2+ imaging is 
presented. The construct contained the Ca2+/calmodulin detector GCaMP5 after a 
GFAP, an astrocytic specific, promoter. Acute slices were                        
made from wild-type mice, 2 – 3 weeks after the rAAV construct was injected into the 
spinal cord dorsal horn. A representative expression of the used construct is shown in 
Fig. 7 B. This picture arrived from an acute slice, which was fixed and stained after the 
Ca2+ imaging experiment. It shows that the amplified GFP expression (green) from the 
Ca2+ indicator overlaid with GFAP positive (red) stained astrocytic constructs (white 
arrow heads).  
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Figure 7: Ca2+ signalling changes in cytoplasm of spinal cord dorsal horn astrocytes 
under neuropathic pain conditions. (A) Injected construct to express cytoplasmic localised 
Ca2+ indicator under GFAP promoter. (B) Immunohistochemistry staining of fixed slices 
expressing indicator (GFP in green) and stained against GFAP (red). Picture shows overlay 
expression of GFAP positive and indicator expressing cells, indicated through white arrow 
heads. (C) Representative stimulation response. Response was defined as peak amplitude 
when higher than 2 x SD of baseline before stimulation. (D) Peak amplitude as the fraction of 
2x SD of 100 Hz for Aβ-, 20 Hz for Aδ- and 4 Hz for C-fibre stimulation under SNI conditions 
(red) and sham/control conditions (black). n = 6 slices for SNI, n = 6 slices for control (from 4 
mice per group) mean ± SEM; two-way ANOVA Bonferonni’s multiple comparison post-hoc test 
for differences between the two tested condition groups, ns > 0.05, * ˂ 0.05 and # = one-sample 
t-test for suprathreshold significance for a hypothetical value of 1. Scale bar = 50 µm. 
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In order to further investigate the Ca2+ signals characteristics, induced by electrical 
dorsal root stimulation, the change of GFP fluorescence (Appendix Figure 1) was 
detected from spinal cord acute slices. To shortly describe the process: the indicator 
construct was injected into the spinal dorsal horn and after 2 – 3 weeks incubation 
time, neuropathic pain through SNI or a sham surgery as control, was induced to the 
mice. According to the literature, 7 days after SNI neuropathic pain is established and 
reached a plateau, which would last for several weeks. At day 7 after SNI or sham 
surgery, acute slices were made and the dorsal root was stimulated like explained in 
the Material and Method section: 20 Hz square pulsed stimulation for 1 s to induce 
stimulation of preferably Aδ-fibres (Sandkuhler et al. 1997), 100 Hz square pulsed 
stimulation for 1 s to evoke signals through Aβ-fibres (Daniele and MacDermott 2009) 
and 4 Hz square pulses or sinusoidal pulses to mainly evoke responses through C-
fibres (Jonas et al. 2018). Fig. 7 C represents an example response and how the 
measured signals were calculated in order to determine if a signal was defined as a 
peak amplitude and if it was a response over the defined threshold of a hypothetical 
value of 1 and therefore defined then as suprathreshold. The baseline was measured 
~10 s before each stimulation and an amplitude was defined as peak amplitude when 
it was bigger than 2x the standard deviation (SD) of the before measured baseline. 
The suprathreshold was calculated when two data points before and after the peak 
were as well bigger than the 2x SD and significantly higher than a hypothetical value 
of 1. 
The stimulation of the dorsal root of acute slices under neuropathic pain as well as 
under control conditions showed that astrocytes responded to all the stimulated fibre 
classes. With an increased stimulation intensity, the peak amplitude responses also 
increased. Fig. 7 D shows that under Aβ-fibre stimulation, responsible for innocuous 
touch sensation, both groups, the neuropathic pain SNI group (red) and the sham 
group (black) had a significant suprathreshold for 0.5, 0.8 and 1 mA stimulation 
intensity. Furthermore, the SNI group showed a trend of decrease in its peak amplitude 
and thus the Ca2+ signalling intensity, compared to the control group, from 0.5 mA 
stimulation intensity on. The neuropathic pain group is for Aβ-fibre stimulation even 
significantly decreased at 1 mA stimulation intensity compared to the sham group.  
Aδ-fibre stimulation resulted in a similar dynamic of Ca2+ signalling in the cytoplasm of 
spinal dorsal horn astrocytes. Both groups, the neuropathic pain and the control group 
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were increased for their peak amplitude and had a significant suprathreshold for 0.5, 
0.8 and 1 mA stimulation intensity. In addition, the SNI group showed a trend towards 
a decrease in its peak amplitude during increased stimulation intensities compared to 
the sham group.  
The last stimulation type, the C-fibre stimulation of 4 Hz, showed as well an increased 
peak amplitude of the Ca2+ signals in the cytoplasm of astrocytes over increasing 
stimulation intensity, with a significant suprathreshold for 0.5, 0.8 and 1 mA for both 
groups, the neuropathic pain treated and the sham treated group. There was no 
detectable difference though between the two groups, thus no observed difference 
between neuropathic pain and sham group when stimulated for C-fibre preferred 
signal transmission into the spinal dorsal horn. 
 
3.1.1.2 Membrane Ca2+ signalling in GFAP-positive cells 
It has been shown, that many Ca2+ signals are happen to be localised at the fine 
processes and endfeet of astrocytes induced by glutamate release from neurons and 
binding to astrocytic receptors (Haydon and Carmignoto 2006; Anderson and 
Nedergaard 2003). This indicates an interesting and possible from soma Ca2+ 
signalling independent role of Ca2+ signalling in astrocytes. To investigate this in 
further detail, the Ca2+ indicator was cloned in combination with a lymphocyte-specific 
protein tyrosine kinase (Lck), which is a membrane bound kinase, so that the indicator 
would be close to the membrane in order to investigate evoked signals at astrocytic 
processes. This membrane bound indicator was expressed under the GFAP promoter 
for astrocytic specific expression (Fig. 8 A). Such an indicator would show in a better 
surface-to-volume ratio the membrane of the astrocytes and thus their processes as 
well as the soma. In comparison, the cytoplasmic localised indicator is mainly present 
in the soma of astrocytes, due to the already mentioned surface-to-volume ratio. 
Immunohistochemistry pictures showed that the expressed indicator (green) 
overlapped with GFAP positive stained (red) constructions, meaning a successful 
expression of the indicator in astrocytes (arrow heads Fig. 8 B). Dorsal root stimulation 
with 20 Hz (preferably resulting in evoked signals transmitted from Aδ-fibres) for 
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duration of 1 s resulted in Ca2+ signals. The response amplitude was higher for 
increased stimulation amplitude. Surprisingly even when the responses seemed to be 
strong for the stimulation, there was no significant suprathreshold detectable (Fig. 8 C 
and D). Only stimulation 0.8 and 2 mA were close to significance as the other 
measured values had to high error bars. Fig. 8 C shows a representative stimulation 
response of Ca2+ signals under 20 Hz stimulation in astrocytes. The behaviour of this 
stimulation evoked responses occurred quite immediately and showed similar peak 
amplitudes compared to the cytoplasmic localised indicator. 
Figure 8: Evoked Ca2+ responses at the membrane of spinal cord dorsal horn 
astrocytes. (A) Injected construct to express Ca2+ indicator under GFAP promoter, bound to 
the membrane. (B) Immunohistochemistry staining of fixed slices expressing indicator (GFP 
in green) and stained against GFAP (red). Picture shows overlay expression of GFAP positive 
and indicator expressing cells. (C) Representative stimulation response here for 20 Hz 1 s 
stimulation with stimulation intensities from 0.2 – 2 mA. (D) Response for stimulation train of 
20 Hz square pulses for 1 s for Aδ-fibre stimulation represented as peak amplitude as fraction 
of 2x SD. n = 5 slices (3 mice) mean ± SEM; # = one-sample t-test for suprathreshold 
significance for a hypothetical value of 1. Scale bar = 50 µm. 
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Even when the investigation of Ca2+ signals in fine processes and endfeet of 
astrocytes would have been very interesting, we figured out that our set-up was not 
suitable for further experiments in this context, as we were not able to focus on single 
endfeet. A confocal microscope with high resolution would have been more suitable. 
For that reason, further planned experiments with this construct were not pursued as 
there would be any kind of specific outcome or added value which could not be 
investigated with the cytoplasmic localised indicator.  
As not all Ca2+ signals, evoked in the processes of astrocytes, would result in Ca2+ 
rises in the cytoplasm (Volterra, Liaudet, and Savtchouk 2014), the cytoplasmic 
indicator represented a stronger way to investigate Ca2+ relevant signals for potential 
gene transcription activation. Nevertheless, here it was shown for the first time that 
dorsal root stimulation of acute slices at a frequency of 20 Hz would result in 
membrane bound Ca2+ indicator activation in astrocytes of the spinal dorsal horn. 
Concerning the Ca2+ signals that only occur in processes but would not reach the 
soma, nothing is known about their purpose or function. This topic will be further 
discussed in later sections. 
 
3.1.1.3 Nuclear Ca2+ signalling in GFAP-positive cells  
Until now there are, to our knowledge, no publications about evoked nuclear Ca2+ 
signals in astrocytes, especially in the dorsal horn of the spinal cord. Only a few groups 
investigated nuclear Ca2+ signals in for example embryonic cortical astrocytes (Zhao 
and Brinton 2003). They showed that for example the G-protein coupled receptor type 
vasopressin receptor (GPCR) causes Ca2+ signalling in astrocytes which induces a 
pathway that includes PKC, CaMKII and ERK1/2 for CREB activation. This leads to 
the suggestion of nuclear calcium driven gene regulation as it was demonstrated in 
neurons (Bading 2013).  
A first indication for potential stimulation driven gene regulation through Ca2+ signalling 
was presented in the previous section where it was shown that dorsal root stimulation 
of all tested preferred fibres would evoke cytoplasmic Ca2+ signals. As Ca2+/calmodulin 
is free to traffic through the nuclear envelope, it is possible that dorsal root evoked 
Ca2+ signals in astrocytes would also cause nuclear Ca2+ signalling and induce activity 
dependent gene transcription, similar to neurons.  
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Figure 9: Ca2+ signalling changes in the nucleus of spinal cord dorsal horn astrocytes 
under chronic pain conditions. (A) Injected construct to express nuclear localised Ca2+
indicator under GFAP promoter. (B) Immunohistochemistry staining of fixed slices expressing 
indicator (GFP in green) and stained against GFAP (red). Picture shows overlay expression 
of GFAP positive and indicator expressing cells. Amount of cells expressing GFP (green) or 
GFAP (red) only are represented in the colour bar on the right. Overlay of GFP expressing 
and GFAP staining is shown in yellow. (C) Stimulation response showed as peak amplitude 
as fraction of 2xSD for 100 Hz Aβ-, 20 Hz Aδ- and 4 Hz C-fibre stimulation under neuropathic 
pain conditions induced through SNI surgery (red) and control conditions (black). n = 6 slices 
(3 mice) for SNI, n = 5 slices (3 mice) for control. (D) Stimulation response showed as peak 
amplitude as fraction of 2x SD for 100 Hz Aβ-, 20 Hz Aδ- and 4 Hz C-fibre stimulation under 
chronic inflammatory pain conditions induced by CFA injection into the hind-paw (green) and 
its PBS control (black). n = 5 (4 mice) for CFA, n = 5 (5mice) for PBS mean ± SEM; two-way 
ANOVA Bonferonni’s multiple comparison post-hoc test for differences between the two tested 
condition groups, ns > 0.05, * ˂ 0.05, ** ˂ 0.005 and # = one-sample t-test for suprathreshold 
significance for a hypothetical value of 1. Scale bar = 50 µm. 
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To investigate this issue, the nuclear localised Ca2+ indicator GCaMP3.NLS (Bengtson 
et al. 2010) was cloned into a rAAV construct under the promoter control of GFAP, to 
be expressed in astrocytes only (Fig. 9 A). The nuclear localisation signal NLS ensures 
that the Ca2+ indicator stayed inside the astrocytic nucleus.  
The immunohistochemistry of spinal cord tissue, injected with this construct, showed 
overlay of cells, expressing the nuclear localised Ca2+ indicator in nuclei with cells 
positive for GFAP staining (Fig. 9 B). The infection rate was detected in about 44 % of 
all identified astrocytes in these staining (Fig. B). This ratio was also representative 
and estimated for all other indicators, as it was only possible to make such a specific 
quantification with the nuclear localised indicator due to the fact of certain localisation 
when stained anti GFAP structures. Still about ~ 8 % were GFP expressing cells but 
with no GFAP positive structure surrounding. This problem of undefined GFP 
expression will be addressed in the next section.  
The stimulation of the dorsal root showed surprising new results. First of all, for all the 
tested fibre stimulations, astrocytes responded with nuclear Ca2+ signalling. Under 
neuropathic pain conditions (Fig. 9 C, red), Aβ-fibres had a significant suprathreshold 
at 0.5 mA stimulation intensity and increased with higher intensities. Compared to the 
sham group (black), there was already a trend towards decreased Ca2+ signalling 
intensities of the response amplitude. The suprathreshold of the sham group was 
significant for 0.8 mA though. Aδ-fibres, thus the first tested nociceptive fibre, showed 
a suprathreshold for 0.5 mA and increasing stimulation intensities under neuropathic 
pain and was significantly decreased compared to the sham group, which showed a 
higher peak amplitude for 0.8 and 1 mA stimulations. The defined suprathreshold for 
those fibres in the control group started, just like the Aβ-fibres with 0.8 mA stimulation.  
For unmyelinated C-fibre stimulation the Ca2+ peak amplitude was for both groups, the 
neuropathic pain and the sham operated group, the same. There was no significant 
difference nor a trend detectable. Both groups had a significant suprathreshold at 0.5, 
0.8 and 1 mA stimulation intensities.  
The investigation of chronic inflammatory pain (Fig. 9 D) showed for all stimulations 
responses but no significant changes between the peak amplitude of the CFA injected 
group (green) and the PBS injected control group (black). Because of the huge error 
bars from the PBS injected group, there was no significant suprathreshold detected 
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for Aβ- and Aδ-fibres, though there is a trend to increased peak amplitude when the 
stimulation intensity is increased. For the PBS group under C-fibre stimulation the 
significant suprathreshold is shown at 0.8 and 1 mA. The CFA group on the other hand 
showed significant suprathreshold for Aβ- and Aδ-fibres for 0.8 and 1 mA stimulation 
intensity and for C-fibre stimulation even at 0.5 mA.  
 
3.1.1.4 Expression of Ca2+ indicator in neurons under GFAP control and 
evoked Ca2+ signals in Aldh1l1 mice 
In the previous section, we showed that we detected GFP expression which were not 
surrounded by positive GFAP stained structures. The question came up what kind of 
cells expressed the indicator under GFAP promoter and did this influence in some way 
the previous recorded Ca2+ signals from astrocytes.  
To approach this question, GFAP:GCaMP3.NLS expressing slices were staining with 
the neuron specific antibody NeuN. That resulted in some overlay of GFP positive cells 
with NeuN positive cells of about ~ 3 % of total cell amount (Fig. 10). Even when those 
cells had a weaker expression (yellow arrow heads) compared to GFP signals from 
non-NeuN positive cells (white arrow heads), the problem had to be approached as it 
was possible that the so far recorded signals from the previous experiments were all 
contaminated in their measured Ca2+ signals with stimulated neurons that expressed 
the Ca2+ indicator as well.  
Figure 10: Astrocytic Ca2+ indicator expression in neurons. GFAP:GCaMP3.NLS GFP 
signal (green) in NeuN positive cells (red). Right bar represents the amount of all detected 
cells, in green showing only GFP positive cells, yellow an overlay of green and red expressing 
or stained cells and red all NeuN positive cells. Yellow arrow heads represent weak 
expressing GFP cells that overlay with NeuN cells, white arrow heads show example of strong 
GFP only expressing cells. Scale bar = 50 µm 
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Figure 11: Ca2+ signalling changes in the nucleus of spinal cord dorsal horn astrocytes 
in Aldh1l1 mice. (A) Injected construct to express nuclear localised Ca2+ indicator. (B)
Immunohistochemistry staining of fixed slices expressing indicator (GFP in green) and 
stained against GFAP for astrocytes (red). Picture shows overlay expression of GFAP 
positive and indicator expressing cells (white arrow heads). (C) Immunohistochemistry 
staining of fixed slices expressing indicator (GFP in green) and stained against NeuN to label 
neurons (red). No overlay was detected. (D) Representative response behaviour for 20 Hz 
(1 s) stimulation with intensities from 0.5 – 1 mA. In grey bars represented the time point of 
stimulation. (E) Stimulation response showed as peak amplitude as fraction of 2x SD for 100 
Hz Aβ-, 20 Hz Aδ- and 4 Hz C-fibre stimulation. n = 7 slices (3 mice). # = one-sample t-test 
for suprathreshold significance for a hypothetical value of 1. Scale bar = 50 µm 
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To investigate this problem and to verify the previous results, the astrocytic specific 
CRE-mouse line Aldh1l1 was now used to express EF1:GCaMP3.3xNLS.myc in a 
floxed tamoxifen injection dependent manner (Fig. 11 A). The procedure with these 
mice was the same as for mice from previous experiments. Only the mice were not 
induced with any pain protocols as we just wanted to verify the evoked Ca2+ signalling 
behaviour of different fibre stimulation, without focusing on the difference of pain 
versus non-pain conditions. The stimulation protocol was as just described in the 
previous sections. Stained slices and observation of the spinal dorsal horn from those 
injected mice showed an overlay with GFAP positive stained astrocytic cell structures, 
meaning that GFAP structures (red) surrounded the nuclear GFP (green) signal from 
the expressed indicator (white arrow heads Fig. 11 B). When stained with NeuN, the 
GFP signal showed no overlay at all with the NeuN signal (red) (Fig. 11 C). This means 
that no Ca2+ indicator was expressed in neurons in this mice-type. 
The response traces from the stimulation were similar to traces from wild-type mice 
that were injected with rAAV induced Ca2+ indicators under the GFAP promoter (Fig. 
11 D). Furthermore, responses were evoked by all the different fibres, resembling the 
evoked responses in mice with nuclear localised Ca2+ indicator under GFAP promoter 
control (Fig. 11 E). Thus, the previous experiments were reliable in respect to 
astrocytic evoked Ca2+ responses in the different cell compartments, even when a 
small amount of indicator was expressed in neurons.  
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3.1.1.5 Multiphasic evoked Ca2+ responses in dorsal horn cells 
During the recordings of especially astrocytic Ca2+ signalling behaviour, we observed 
that sometimes the cells responded to one stimulation with not only one single peak 
amplitude, but with a second mostly smaller peak (Fig. A). This multiphasic evoked 
Ca2+ response was not detected in all analysed slices. Also not for all stimulation 
intensities, this second peak occurred. Mainly for stimulation intensities between 0.2 
and 1 mA the second response peak would develop. Therefore, it was detected under 
all stimulated fibre classes (Fig. B). From the total amount, the most second peaks 
were detected at 0.8 mA stimulation intensity for all the tested fibre classes. The 
presented data did not distinguish between pain protocols or their appropriate controls. 
All detected second peaks were plotted in groups of the stimulated fibre class (Aβ-, 
Aδ- and C-fibre) from all used Ca2+ indicator type (GCaMP5 or GCaMP3.NLS) and the 
pain model (chronic inflammatory pain or neuropathic pain).  
Figure 12: Multiphasic evoked Ca
2+
 responses. (A) Representative example of second peak 
after first evoked response through DR stimulation. Presented example for 4 Hz stimulation 
with intensities between 0.5 and 1 mA of an GFAP:GCaMP5 expressing acute slice after sham 
surgery. (B) Graph shows distribution of second peak occurrence as peak amplitude as fraction 
of 2x SD from all analysed slices with Ca
2+
 indicator expression in astrocytes. Groups divided 
into stimulated fibre classes: 4 Hz for C-fibre (black), 20 Hz for Aδ- (grey) and 100 Hz for Aβ-
fibre (white). n = mean ± SEM.  
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3.1.1.6 Longer lasting Aδ-fibre stimulation 
In order to mimic a more physiological stimulation, we introduced a stimulation of 20 
Hz squared pulsed but instead of only stimulating for 1 s, the dorsal root was 
Figure 13: Long lasting Aδ-fibre stimulation. (A) Representative example of Ca2+ 
response on 20 Hz stimulation for 10 s for each intensity (black horizontal bar). Presented 
is a GFAP:GCaMP5 acute slice stimulation with visible response as % of ∆F/F for intensities 
from 0.2 – 1 mA. (B) Graph shows peak amplitude as fraction of 2x SD for the 20 Hz 10 s 
stimulation responses for the three groups: GFAP:GCaMP5 SNI/sham (light grey), 
GFAP:GCaMP3.NLS SNI/sham (black) and GFAP:GCaMP3.NLS CFA/PBS (grey). n = 6 for 
each group. Mean ± SEM. ns > 0.05, # ˂ 0.05, ## < 0.005, ### ˂0.0005, #### < 0.0001; #, 
§ and $ = one-sample t-test for suprathreshold significance for a hypothetical value of 1.  
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stimulated at the end of each stimulation protocol for 10 s with this frequency with all 
the before used stimulation intensities. The idea was that a normal stimulation input to 
the body would normally last longer than 1 s. Here, we observed an interesting 
phenomenon. The Ca2+ response and peak amplitude were much higher than for the 
20 Hz 1 s stimulation (normal Aδ-fibre stimulation) for all the tested indicators 
(cytoplasm and nucleus) (Fig. 13 A). One example trace showed how the amplitude 
seemed to build up and increased over time of stimulation to reach a peak or 
sometimes a plateau. We also observed “drops” in the recorded responses (data not 
shown) where the recorded Ca2+ signal decreased below 0 during the whole  
stimulation and went back to its baseline after stimulation. These data were excluded 
from measurements. The remaining measurements were pooled together into three 
groups: GFAP:GCaMP5 (SNI and sham together), GFAP:GCaMP3.NLS (SNI and 
sham together) and GFAP:GCaMP3.NLS (CFA and PBS together) (Fig. 13 B). Except 
for the Ca2+ indicator localised in the cytoplasm, all other groups reached a significant 
suprathreshold from 0.1 mA stimulation intensity on. GFAP:GCaMP5 reached the first 
significant suprathreshold at 0.2 mA. The curve increased and reached its maximum 
for the two groups with Ca2+ indicator localised in the nucleus at 0.5 mA. The indicator, 
expressed in the cytosol, reached its maximum at 0.8 mA. 
 
3.1.2 Ca2+ signalling in parvalbumin-positive neurons 
3.1.2.1 Cytoplasmic Ca2+ signalling in parvalbumin positive cells under 
chronic inflammatory pain conditions 
As excitatory neurons showed increased Ca2+ signalling under chronic inflammatory 
pain conditions (Simonetti et al. 2013) and as we observed interesting Ca2+ signalling 
behaviour in astrocytes, it was of a high interest to investigate a group of inhibitory 
neurons in the spinal dorsal horn for their fibre evoked Ca2+ signalling under chronic 
pain conditions. In addition, it has already been shown that under certain chronic pain 
conditions inhibitory neurons in the CNS are impaired in their function and total number 
of cells (Basbaum). This made the investigation of inhibitory neurons even more 
interesting. For the purpose to study this open question, a subtype of inhibitory 
neurons, a parvalbumin (pv) Cre-mouse line, kindly provided by the collaborating 
group from Prof. Dr. Rohini Kuner (Pharmakologisches Institut, Heidelberg Universität, 
Germany) was used. The mice were injected with a rAAV-construct in a Cre 
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recombinase-dependent manner under control of the human EF1α promoter in order 
to express a cytoplasmic Ca2+ indicator inside pv-positive cells (Fig. 14 A), including a 
nucleus export signal (NES) to keep the indicator in the cytosol only. In the fluorescent 
pictures, the expression of the GCaMP3.NES was visible in the spinal dorsal horn (Fig. 
14 B). As for the dorsal root stimulation, all stimulated fibre types, Aβ-, Aδ- and C-
fibres, evoked Ca2+ signalling in the spinal dorsal horn pv-neurons inside the 
cytoplasm (Fig. 14 C). The peak amplitude, presented as the fraction of 2x SD, 
Figure 14: Ca2+ signalling changes in the cytoplasm of spinal cord dorsal horn pv-
positive inhibitory neurons mice. (A) Injected construct to express cytosolic localised Ca2+
indicator with nuclear export signal (NES). (B) Image of fixed slices expressing indicator (GFP 
in green) in spinal dorsal horn. Dotted line indicating border of dorsal horn. (C) Stimulation 
response showed as peak amplitude as fraction of 2x SD for 100 Hz Aβ-, 20 Hz Aδ- and 4 Hz 
C-fibre stimulation. There was no detectable difference between the chronic inflammatory 
group, injected with CFA (green) and the PBS injected control group (black). n = 7 slices (5 
mice) for CFA and n = 4 slices (4 mice) for PBS; ns > 0.05. # = one-sample t-test for 
suprathreshold significance for a hypothetical value of 1. Scale bar = 50 µm 
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increased the higher the stimulation intensity was. Under PBS conditions there was 
no suprathreshold detectable for none of the tested fibres. Under CFA (chronic 
inflammatory pain) conditions suprathresholds were measured. For Aβ-fibres 
stimulation, the suprathreshold of the CFA treated group was significant for 0.5 and 
0.8 mA stimulation intensity. Aδ-fibres stimulation led to suprathreshold for intensities 
between 0.5 – 1 mA for acute slices from CFA treated mice. Also for C-fibre 
stimulation, the CFA injected group showed suprathreshold for 0.8 and 1 mA 
stimulation intensity. 
The tested pain model was the one for chronic inflammatory pain, injection of CFA into 
the hind paw. There was no difference in any of the stimulated fibres between the CFA 
group and the PBS injected control group. That was similar to the tested chronic 
inflammatory pain in astrocytes. 
Further experiments showed that neuropathic pain seems to have more influence onto 
the Ca2+ signalling behaviour of pv-cells, but this will be discussed in a later section 
(3.2.1 Npas4 expression under chronic inflammatory and neuropathic pain). 
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3.1.2.2 Spontaneous Ca2+ signals in parvalbumin-positive neurons 
In addition to the evoked signals that were presented above, we observed 
spontaneous activity of pv-positive cells in the spinal cord dorsal horn. This 
spontaneous activity was different in many cells. The pattern, as well as the duration 
of the Ca2+ signal was highly diverse. The spontaneous activity was more prominent 
at the beginning of the recording procedure and lost its frequent activity during the 
stimulation protocol. Examples of Ca2+ imaging from cells with spontaneous activity 
are represented in Fig. 15. An example slices included a PV-positive neuron with very 
regular spontaneous Ca2+ signals that held its high Ca2+ level for 15 – 20 s and then 
decreased back to its Ca2+ baseline level. In the presented time window of 200 s, the 
cell (Fig. 15 A, red) had seven Ca2+ signals. A second cell of the same slice (blue) had 
no spontaneous activity during the first 100 s and then showed five peaks of Ca2+ 
signals in 50 s. These signals looked in their dynamics (duration of the signal) very 
different from the cell that is represented in red. 
Figure 15: Spontaneous Ca2+ signalling in the cytoplasm of spinal cord dorsal horn pv-
positive inhibitory neurons of mice. Displayed are two example slices with recorded 
spontaneous Ca2+ signalling before and during dorsal root stimulation. Every colour indicates a 
single cell. (A) Presented are two cells from an acute slice with one cell (red) which had regular 
and long lasting Ca2+ signals between 15 – 20 s. Second cell (blue) showed a sudden spiking of 
Ca2+ signals of 5 peaks in 50 s. (B) One cell (black) showed multiple spiking of Ca2+ signals with 
silencing in between. Peak number varied from 3 – 6 peaks for each of the 5 presented activity 
periods in the presented time window. Second cell (green) showed no spontaneous activity but 
evoked responses for 20 Hz stimulation with intensities of 0.5 – 1 mA (grey bars). Y-axes 
indicates Ca2+ signals as amplitude ∆F/F in % and X-axes indicates time in s. 
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A second example slice from a different mouse showed a PV-positive neuron (Fig. 15 
B, black) with again regular spontaneous activity but instead of holding a high Ca2+ 
level during main activity periods, the cell had five main activities in the displayed time 
window of 200 s which showed decreases in the peak amplitude during each main 
activity that resulted in three to six peaks during these activities where the signal 
decreased but not completely to baseline level. After each main activity the Ca2+ level 
decreased back to baseline. A second cell from the slice (green) did not show 
spontaneous activity but evoked responses for stimulation of 20 Hz and only for the 
intensities of 0.5 – 1 mA. 
 
 
Figure 16: Npas4 expression changes during chronic inflammatory and neuropathic 
pain. Dorsal horn tissue from lumbar area L3-L5 from the spinal cord was analyzed after the 
indicated pain protocols by qRT-PCR at the mentioned time points. (A) Graph represents 
relative mRNA expression of CFA treated mice over PBS (1 h after injection) at different time 
points in different grey scales (1 h, 3 h and 6 h after CFA injection) for the expression of Npas4, 
Bdnf and cFos. Dotted line represents the baseline level (defined by 1 h PBS injection). (B)
Graph represents relative Npas4 expression (SNI over sham group) from the ipsi lateral side 
(white) at different time points after surgery, compared to the Npas4 expression of the contra 
lateral side (grey). A: n = 5 (CFA/PBS) or B: n = 4 (SNI/sham); mean ±SEM; two-way ANOVA 
Bonferonni’s multiple comparison post-hoc test for differences between the two tested 
condition groups, ns > 0.05; * < 0.05; *** < 0.0005. 
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3.2 Consequences of Ca2+ signalling in spinal dorsal horn neurons 
3.2.1 Npas4 expression under chronic inflammatory and neuropathic 
pain 
It was shown that inhibitory neurons in the spinal cord dorsal horn are impaired 
regarding their synaptic activity and their amount under neuropathic pain (Basbaum et 
al. 2009). Inhibitory neurons showed a decreased number of synapses and decreased 
total number of cells under neuropathic pain. As presented in the previous section 
(3.1.2 3.1.2 Ca2+ signalling in parvalbumin-positive neurons), Ca2+ signals in pv-
positive cells in the spinal cord dorsal horn were evoked by dorsal root stimulation. 
This might indicate that there is a direct input from the periphery to inhibitory neurons 
in the spinal dorsal horn, which are then part of the pain circuit system. These 
stimulations from the periphery induced cytoplasmic Ca2+ increases in pv-positive 
cells. Cytoplasmic Ca2+ signalling leads to nuclear Ca2+ signalling, as the 
Ca2+/calmodulin complex can freely travel through the nuclear pore complexes. The 
nuclear Ca2+ signalling leads to gene expression respectively (Eder and Bading 
2007).  
This strongly suggests that peripheral activity such as signal transmission through 
fibres like Aβ-, Aδ- and C-fibres caused neuronal activation of inhibitory neurons in the 
spinal dorsal horn. What role do these neurons play in terms of their Ca2+ signalling 
induced gene transcription under chronic pain? To investigate alterations of gene 
expression in cells that drive inhibitory balance in the neuronal circuit of the dorsal 
horn under chronic pain conditions, wild-type mice were either treated with the SNI or 
sham surgery for neuropathic and a different group of animals with either CFA or PBS 
injection to elicit chronic inflammatory pain. The mice spinal cord dorsal horn from 
lumbar section L3-L5 were collected at different time points after treatment.  
Npas4 expression is responsible for inhibitory balance of the neuronal circuit after 
neuronal activity only (Sun and Lin 2016). It increases the amount of excitatory 
synapses onto inhibitory neurons and increases the amount of inhibitory synapses 
onto excitatory neurons. Thus, Npas4 regulates the homeostatic balance of inhibition 
in the CNS. In our experiment, focus was put onto the expression of Npas4 in the 
collected tissue. Npas4 expression is not only dependent from neuronal activity but 
specifically from Ca2+ signalling (Zhang et al. 2009). As presented above, cytoplasmic 
Ca2+ in inhibitory neurons can be evoked through dorsal root stimulation, mimicking 
74 
 
peripheral inputs to the CNS. Thus, the Ca2+ signalling would cause nuclear Ca2+ rises 
and finally gene transcription activity. The role of Npas4 in the neuronal circuit in the 
spinal cord dorsal horn was therefore of great interest, particularly under different pain 
models.  
The qPCR results from the collected spinal cord tissue from mice that were treated 
with CFA injections showed a significant increase of Npas4 mRNA already 1 h after 
injection in comparison to the PBS injected mice at the same time point (Fig. 16 A). 
This result is in agreement with other publications showing that, Npas4 is an IEG 
already expressed ~ 5 min after neuronal activity (Maya-Vetencourt 2013). After 3 h, 
the relative expression of Npas4 returned to baseline levels. Bdnf was not significantly 
induced. cFos was highly significantly induced after 1 h and returned to baseline after 
3 h.  
Interestingly, in the neuropathic pain model, where spinal cord tissue was collected 
after different time points after SNI or sham surgery, Npas4 expression was reduced 
for both the treated (ipsilateral) and not treated (contralateral) at day 1 after surgery. 
While the ipsilateral side remained reduced at day 3 after surgery, the not treated side 
returned to baseline levels (Fig. 16 B) and stayed at that level up to day 10 after 
surgery. At day 10, the relative Npas4 expression of both the ipsilateral side and the 
non-treated contralateral side was equally at baseline levels. These results were 
generated with Dr. Anna Hertle.  
3.2.2 Manipulation of expression of Npas4 in vitro 
The findings from the previous section, that Npas4 expression was impaired under 
neuropathic pain in the early phase of pain development, indicated an important role 
of Ca2+ signalling induced Npas4 in the spinal dorsal horn functional circuit. To further 
investigate the role of NPAS4 in the context of chronic pain, we developed a rAAV-
shNpas4, a dominant-negative NPAS4 construct and a Npas4 over-expression rAAV, 
together with their equivalent controls. First, we tested the constructs for their function 
in hippocampal and later in spinal cord cell culture.  
First, the shNpas4 construct was tested. The sh-sequence was expressed under an 
U6 promoter. For visualisation, added to the construct was a GFP sequence under the 
control of a CMV promoter (Fig. 17 A).  
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Figure 17: Relative 
expression levels after 
rAAV shNpas4 treatment 
in vitro. (A) shNpas4
construct with GFP 
sequence for visual labeling. 
Pictures show example 
expression of construct in 
hippocampal primary neuron 
culture. (B) shUNC construct 
with GFP sequence for 
visual labeling. Pictures 
show example expression of 
construct in hippocampal 
primary neuron culture. (C)
Relative gene expression of 
Npas4, Nptx2, Arc and FosB
from primary hippocampal 
neuron culture that had 
shNpas4 (red), shUNC 
(grey) or no rAAV (white). 
Graphs show relative gene 
expression with or without 2 
h BIC treatment. n = 8 for all 
groups; mean ±SEM; two-
way ANOVA Bonferonni’s 
multiple comparison post-
hoc test for differences 
between the two tested 
condition groups, ns > 0.05, 
* ˂  0.05, ** < 0.005. scale bar 
= 100 µm. 
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The control construct consisted of the same promoters and fluorescent protein, with a 
scrambled version of the sh-sequence (Fig. 17 B), established in our lab and not 
targeting any mRNA, thus not having an effect on any other gene expression. The 
expression levels of the rAAV constructs, the shNpas4 as well as its control construct, 
were visible in primary hippocampal mouse cell cultures (Fig. 17 A, B). In order to test 
the function of the constructs, cells were transfected with rAAV constructs (DIV 3) and 
Figure 18: in vitro manipulation of NPAS4. (A) rAAV constructs for NPAS4 manipulation. 
(B) Immunohistochemistry pictures from primary hippocampal cells expressing rAAV 
constructs from (A) and stained against HA. (C) Protein levels of primary hippocampal cell 
culture for NPAS4 and TUBULIN when treated with no virus, OE-NPAS4 or control construct 
and ± BIC treatment. n = 2; scale bar = 100 µm. 
77 
 
treated for 2 h with bicuculline (BIC) at DIV 10 to induce more excitatory neuronal 
activation and thus neuronal depolarisation through inhibition of GABA receptors. The 
result showed that the relative expression of the tested genes in hippocampal cell 
culture did not change for Npas4 expression (Fig. 17 C). The shNpas4 construct did 
not significantly decreased the relative mRNA expression of Npas4 compared to its 
proper control: shUNC. We detected a significant decrease of the relative Npas4 
expression under shNpas4 influence compared to the cultures that were not treated 
Figure 19: in vitro manipulation of NPAS4 in primary spinal cord culture. (A) Fluorescent 
pictures from rAAV constructs expressing in primary spinal cord cell culture. (B) Protein level
of NPAS4 (~ 130 kDa) and TUBULIN (~ 55 kDa) of primary hippocampal cell culture when 
transfected with HA-control rAAV or OE-NPAS4 rAAV and treated with ± BIC. n = 2; scale bar 
= 100 µm. 
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with rAAVs. Also other Npas4-dependent genes such as Nptx2 were not significantly 
decreased compared to the controls when treated with shNpas4. The only significant 
difference between shNpas4 and shUNC treated cells was detected for Arc and FosB 
expression. In both cases the shNpas4 treated cultures showed increased levels of 
those tested genes.  
In conclusion, the shNpas4 construct resulted unsuitable for further experiments as 
the control.  
That led to a development of a dominant-negative (dn) Npas4 construct. The 
dominant-negative construct was made of a sequence to act antagonistically on the 
wild-type expressed NPAS4 protein and would like this make it not functional acting 
anymore. The construct was set behind a human synapsin (hSyn) promoter to be 
expressed in any kind of neuron, inhibitory as well as excitatory. In addition the dn-
NPAS4 had an HA-tag and afterwards, also under hSyn control, a tDimer, for visually 
detectable red expression (Fig. 18 A – B).  
 
To not only block NPAS4 functionality but also to try to rescue the decreased 
phenotype from under the neuropathic pain conditions, we developed an over-
expression construct in order to have an increased amount of NPAS4 protein 
compared to the baseline expression. The over-expression virus (OE-Npas4) was 
placed under a hSyn and in addition, it was coupled to an HA-tag. In the end the 
construct had, as well under the hSyn promoter, a tDimer, for red visualisation of the 
expression in cells later on. The control construct consisted of only an HA-tag under 
hSyn promoter and a tDimer, also under hSyn control. Like this it functioned as control 
construct for the dn-NPAS4 rAAV as well as for the OE-NPAS4 (Fig. 18 A – B). 
 
The function of the constructs were tested for their expression and function in primary 
hippocampal mouse cell culture. Fig. 18 B shows the expression level of the tDimer 
from the different constructs in the neurons. There was an overlay of the tDimer 
expression and a staining against the HA.tag. In addition, the protein levels of NPAS4 
were tested. In primary hippocampal cell culture basal level of NPAS4 under 
conditions of no virus transfection, transfection with the control or the dn-construct 
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were not elevated but the OE-NPAS4 construct showed a strong band positive for 
NPAS4-antibody. Under BIC treatment, which led to neuronal activation, the NPAS4 
expression was visible for all tested constructs, proving again that NPAS4 expression 
is dependent on neuronal activity. 
The same tests were performed in primary spinal cord culture. The expression levels 
of the different constructs was visible in the cells and also the protein levels were 
similar to the expression levels that were already detected under BIC or without BIC 
treatment in primary hippocampal cultures (Fig. 19).  
Figure 20: NPAS4 changes in spinal dorsal horn under different rAAV constructs. Dorsal 
horn tissue from lumbar area L3-L5 from the spinal cord was analyzed after the injection of 
rAAV constructs for over expressing NPAS4, rAAV with a control plasmid and a dominant-
negative Npas4 construct. (A) Graph represents two mice for each construct and their levels 
of NPAS4 proteins ( ~ 130 kDa). For control expression, TUBULIN expression ( ~ 55 kDa) was 
tested. (B) Pictures show representative expression of OE-NPAS4 construct and control 
construct in the spinal dorsal horn of mice that were used for behavioural experiments. Visible 
are tDimer expression from injected constructs and Hoechst from staining. Scale bar 100 µm. 
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3.2.3 Npas4 manipulation in vivo 
The control construct and the OE-NPAS4 construct were tested for their effect in vivo. 
In vivo the constructs were injected with rAAVs into the spinal cord of two WT mice 
each and after three weeks of expression time the mice were perfused and the spinal 
dorsal horn was collected for protein level analysis. The results showed that the OE-
NPAS4 construct successfully induced higher levels of baseline NPAS4 compared to 
the control construct and the dn-Npas4 construct (Fig. 20 A).  
 
The basal level of NPAS4 is too low to be visible on a western blot. As control for 
protein expression, tubulin was used and detectable in all constructs. 
The expression of the constructs was also shown in fluorescent pictures that were 
made after behavioural experiments. Fig. 20 B shows the tDimer expression of the 
HA.control construct and the OE-NPAS4 construct. Under both constructs, expression 
was visible in many cells of the mouse spinal dorsal horn in superficial as well as in 
deeper dorsal horn laminae.  
 
3.2.4 Npas4 over expression in vivo under neuropathic pain conditions 
In section 3.2.1 it was presented that Npas4 expression is altered under early phases 
of neuropathic pain conditions. For that reason, the Npas4 influence under neuropathic 
pain was tested. The hypothesis was to increase the protein level of NPAS4 in spinal 
dorsal horn cells, introduced by the rAAV construct which was injected into the spinal 
cord dorsal horn of WT mice just as described in the previous sections, related to Ca2+ 
signalling, in order to rescue neuropathic pain, induced through SNI surgery. The 
theory was, that through the increase of NPAS4 in the spinal dorsal horn, it would lead 
to an increase of the inhibitory balance and thus would buffer the normally alteration 
of the inhibitory system under neuropathic pain, as described in the introduction. As a 
control, another group of WT mice would be injected with the control construct but 
handled the same way, and would also receive SNI surgery. Mice were tested for 
mobility behaviour through catwalk testing previous to spinal cord injection and 
previous to SNI but after injection of the rAAV constructs. Also at day 4 after SNI 
surgery the mobility behaviour was tested on the catwalk (Fig. 21). In addition, 
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mechanical pain threshold was tested with von Frey filaments as well as the thermal 
pain threshold through cold plate as baseline before and after injection to rule out any 
effect of the rAAV injection into the spinal dorsal horn. Both pain behaviour tests are 
known to be increased in their mechanical threshold or thermal hypersensitivity after 
neuropathic pain induction. To investigate the effect of Npas4 over expression on 
neuropathic pain conditions, the previous developed and tested tools, the rAAV 
constructs of OE-NPAS4 and HA.control, were injected into the left side lumbar part 
L3-L5 of WT mice spinal cord dorsal horn. 10 days after injection, baseline behaviour 
for the indicated behavioural tests (catwalk, von Frey filaments and cold plate) (Fig. 
21 B) were tested. At day 15 after spinal cord injection, a day were the expression 
level of the rAAV constructs would already be at a high level, SNI surgery was 
introduced to the injected mice. Mechanical pain threshold through von Frey filaments 
and thermal pain threshold through cold plate were tested at day 2, 3, 5, 7 and 10 after 
Figure 21: Experimental procedure of OE-NPAS4 injection and pain behaviour. (A) For 
the neuropathic pain model, baseline behaviour was measured before and after injection to 
rule out any effect of the rAAV injection itself. Injected were OE-NPAS4 construct or HA.control 
construct. Two weeks after injection, SNI surgery was performed to induce neuropathic pain 
to all the mice. Pain behaviour was measured at day 2, 3, 4, 5, 7 and 10 after SNI surgery. (B)
The tested pain behaviours were von Frey for mechanical sensitivity, cold plate for thermal 
sensitivity and catwalk for motoric impairment and behaviour.  
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SNI surgery. In addition, catwalk was tested to prove impaired walk behaviour after 
Figure 22: Pain behaviour under von Frey and cold plate tests. (A) Measured mechanical 
pain threshold of 40 % for different fibre strengths at different time point: baseline before rAAV 
injection, baseline after rAAV injection and measurements at day 2, 3, 5, 7 and 10 after SNI 
surgery. Two groups are displayed: OE-NPAS4 (grey) expressing animals or HA.control 
(white) expressing animals. No significant differences detectable. (B) Measured mechanical 
pain threshold of 60 % for different fibre strengths at different time point: baseline before rAAV 
injection, baseline after rAAV injection and measurements at day 2, 3, 5, 7 and 10 after SNI 
surgery. No significant differences if not indicated otherwise. (C) Area under the curve of 
mechanical stimulus-response at different indicated time points. Not significant if not indicated 
otherwise. (D) Tested thermal hypersensitivity was measured as response latency in s at the 
indicated time points. No significant differences.  n = 3 (OE-NPAS4 group) and n = 5 (control 
group), ± SEM; significance compared to the own baseline before injection of a group was 
tested with two-way ANOVA Bonferonni’s multiple comparison post-hoc test: ns > 0.05, # ˂ 
0.05, ## < 0.005, ### ˂0.0005, #### < 0.0001 for control group and same p-values for 
OENpas4 group with indicated symbol: $ ; significance compared between the two animal 
groups: two-way ANOVA Bonferonni’s multiple comparison post-hoc test for differences 
between the two tested condition groups: ns > 0.05, * ˂ 0.05, ** < 0.005, *** ˂0.005. 
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SNI surgery. Fig. 22 A showed no significant increase of the mechanical pain 
hypersensitivity at a threshold of 40 % tested for the different strengths of von Frey 
filaments. There is a visible decrease of the control group after SNI surgery compared 
to the basal levels.  For the mechanical pain hypersensitivity at a threshold of 60 % 
tested for the different strengths of von Frey filaments there was a detectable decrease 
of the threshold from the control group compared to the OE-NPAS4 injected group for 
days 5 and 7 after SNI surgery and a trend of decrease for day 10 after surgery (Fig. 
22 B). The area under the curve of the mechanical stimulus-response showed even 
better the effect of the OE-NPAS4 construct on the mechanical pain behaviour. There 
was no difference between the groups and the two measured baselines. But already 
at day 2 after SNI surgery, the control group showed significant increased mechanical 
hypersensitivity (Fig. 22 C). This hypersensitivity increased over the following days. 
The OE-NPAS4 injected group showed on the other hand no significant increase of 
hypersensitivity compared to the baseline levels at any days after surgery. At day 5 – 
10 after surgery the control group showed increased hypersensitivity not only 
compared to the baseline levels but also compared to the OE-NPAS4 group.  
The tested thermal hypersensitivity showed no difference between the two different 
animal groups. The animals of the control group showed significant difference 
compared to the baseline measurements, when tested at the different time points after 
SNI surgery. So thermal hypersensitivity was increased by measured response 
latency of paw withdraw when placed onto the 4°C cold plate (Fig. 22 D). 
The catwalk showed no impairment of run duration or run average between the groups 
or the tested time points (Fig. 23 A and B). For the other tested parameters (print area, 
swing speed, step cycle and single stance) (Fig. 23 C – F) there was a significant 
decrease between the two baseline time points and day 4 after SNI surgery for both 
groups of animal. That showed that the left hind paw, that underwent SNI surgery, was 
impaired in its motor function, represented through the swing speed, the step cycle 
and the single stance (Fig. 23 D – F). The print area is an indicator for the intensity of 
usage of the paw. The hind paw of both groups showed significant decreased print 
areas for both groups compared to the baseline (Fig. 23 C). Examples of the 
visualisation of the catwalk video as well as the print area and the print intensity can 
be found in Appendix Figure 2. 
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Figure 23: Catwalk behaviour. Mice were tested on the catwalk before rAAV injection, 10 
days after rAAV injection and 4 days after SNI surgery (d4). Mice were represented in the two 
groups: OE-NPAS4 injected mice (grey) and control construct injected mice (black). (A) Run 
duration in s for the indicated time points. (B) Run average in cm/s. (C) Print area of the hind 
paws calculated as the ipsi lateral side (rAAV injected and SNI surgery side) over the contra 
lateral side as cm2. (D) Swing speed of the hind paws calculated as the ipsi lateral side (rAAV 
injected and SNI surgery side) over the contra lateral side as cm/s. (E) Step cycle of the hind 
paws calculated as the ipsi lateral side (rAAV injected and SNI surgery side) over the contra 
lateral side in s. (F) Single stance of the hind paws calculated as the ipsi lateral side (rAAV 
injected and SNI surgery side) over the contra lateral side in s. No significant differences 
between OE-NPAS4 and control group in all the tested parameters.  n = 3 (OE-NPAS4) and n 
= 5 (control), ± SEM; significance compared to the own baseline before injection of a group 
was tested with two-way ANOVA Bonferonni’s multiple comparison post-hoc test: ns > 0.05, #
˂ 0.05, ## < 0.005, ### ˂0.0005, #### < 0.0001 for control group and same p-values for OE-
NPAS4 group with indicated symbol: $; significance compared between the two animal groups: 
two-way ANOVA Bonferonni’s multiple comparison post-hoc test for differences between the 
two tested condition groups: ns > 0.05. 
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4. Discussion 
The experiments presented in this thesis gave an insight into the circuit mechanisms 
of the development and maintenance of different chronic pain models. We investigated 
the Ca2+ signals of astrocytes and PV-positive neurons in the spinal dorsal horn. We 
showed that fibre stimulation of different fibre classes can evoke Ca2+ signals in 
astrocytic cytosol and nucleus. Furthermore, we detected decreased Ca2+ signalling 
in the cytoplasm of astrocytes under neuropathic pain conditions when stimulated with 
frequencies mainly recruiting Aβ-fibres and Aδ-fibres concerning nuclear Ca2+ 
signalling. For chronic inflammatory pain conditions, we didn’t find any impairment in 
Ca2+ signalling in astrocytes as well as in PV-neurons.  
Still, NPAS4, a protein, expressed specifically after Ca2+ signalling in neurons and 
responsible for a homeostatic balance in favour of inhibition, was decreased under 
neuropathic pain conditions. Further investigation on NPAS4 showed that over 
expressing NPAS4 in the spinal dorsal horn of mice rescued mechanical 
hypersensitivity but not thermal hypersensitivity or motoric impairment after 
neuropathic pain induction. 
 
4.1 Challenges during experiments 
Injections into the spinal dorsal horn of mice are a challenging procedure. Due to 
respiration movements and the difficulty to fix the mice back like it is done for brain 
injections, a precise depth cannot be assured for all injections, compromising the 
quality of the procedure. In addition, touching the dorsal horn with an injection needle 
can lead to sudden movements of the mice even under deep anaesthesia because of 
a mechanical stimulation of the neurons. These mechanical stimulations might activate 
neurons that are connected via interneurons with deeper motor neurons in the ventral 
part of the spinal cord, which then leads to a sudden movement (possibly a reflex). 
Nevertheless, we confirmed out method by injecting the Ca2+ indicators and labelling 
C-fibre endings with Isolectin B4 (Fig. 6). These results approved our methods for all 
coming experiments. 
Also during imaging of Ca2+ some unexpected difficulties occurred. Unfortunately due 
to the set-up and the fact that the software control of the stimulator was not directly 
connected to the imaging recording set-up, it was difficult to determine an accurate 
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time point of stimulation and its relation to the evoked Ca2+ response. The response 
time can be set to ~ 1 – 3 s after stimulation. Still as it is under debate how fast 
astrocytic Ca2+ signals can occur, it would have been very interesting to determine a 
specific time point of Ca2+ signal after stimulation. 
During live imaging of acute slices with indicators that were expressed in the cytosol 
or at the astrocytic membrane, it turned out to be difficult to make out single cells or 
fine processes. In contrast, expressing cells appeared cloudy during imaging if at all 
as the baseline level of Ca2+ in astrocytes is very low. With the used wide-field 
microscope resolution it was impossible to make out single or fine processes, as 
focusing on fine processes in the relatively thick slices is not possible with the set-up 
we used. A confocal microscope with high recording frequency would be more suitable 
to investigate Ca2+ in fine processes and astrocytic endfeet. 
Another problem was the neuronal expression of our used indicators under the GFAP 
promoter. Even when further experiments with the Aldh1l1 cre-mouse line showed that 
the evoked Ca2+ behaviour was similar in both mice, WT mice with injected indicator 
under GFAP promoter and Aldh1l1-mice with injected indicator in a floxed manner, for 
further experiments it is necessary to use Aldh1l1-mice preferably as the possible 
contamination of neuronal effects under the GFAP promoter cannot be excluded. 
During stimulation with 20 Hz for 10 s we observed in some acute slices a drop instead 
of an increase in the evoked Ca2+ signal. We believe that the strong stimulation led to 
a heat up of the electrode which then formed air bubbles at the tip of the stimulation 
pipette and thus pressed down the tissue during the recording which was detected as 
a decrease below 0. After this stimulation we often observed bubbles at the tip of the 
electrode even when the DR was still well attached to the spinal cord slice as well as 
to the stimulation electrode. Furthermore, for this stimulation it is possible that through 
such a high and long, thus intense stimulation, not only Aδ-fibres but also other fibre 
classes like Aβ- and C-fibres were recruited during the stimulation. Thus, it is not clear 
which fibre class evoked this strong Ca2+ response. It is possible that of one fibre class 
over a longer stimulation time more fibres are recruited and that this would as an 
addition increase the detected signal or if all fibre classes are recruited over the 
stimulation time and would result in such a high evoked Ca2+ response. This problem 
could be addressed by specifically blocking different fibre classes and investigating 
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the Ca2+ signalling behaviour for only one active fibre class. The long stimulation 
protocol should also be performed independently of the other stimulation protocols in 
order to directly stimulate a “naïve” acute slice, which was not stressed through 
previous stimulations. This could prevent the occasionally bubble formation at the tip 
of the electrode pipette. 
It is also possible that the strong stimulation and the long and stressful stimulation 
protocol impaired the quality of the cells and the whole acute slice tissue.  
 
4.2 Ca2+ signalling in astrocytes 
4.2.1 Ca2+ signals in astrocytes induced through fibre stimulation 
Astrocytes are known to not only support but also communicate with neurons through 
Ca2+ signals or the release of gliotransmitters initiated by Ca2+ elevations in astrocytes. 
Still it is under debate if they play a crucial role in for example learning and memory 
contexts (Agulhon, Fiacco, and McCarthy 2010). When it comes to chronic pain and 
the role of astrocytes in this context, there are even more questions unresolved. It was 
shown that astrocytes respond with astrogliosis and increased Ca2+ signalling and 
transmitter release under inflammatory pain conditions in the brain (Hansson 2010) 
and in the cortex under neuropathic pain (Kim et al. 2016). Also slight plasticity 
changes in the spinal cord dorsal horn (Ikeda, Kiritoshi, and Murase 2012) were shown 
under inflammatory and neuropathic pain conditions. Still, especially in the spinal cord, 
there is not much known about the role of Ca2+ signalling in astrocytes in the context 
of chronic pain. This thesis offers a new perspective and new insight into that matter. 
The stimulation of the DR from acute slices showed for all the different preferable fibre 
classes, Aβ-, Aδ- and C-fibre, evoked Ca2+ signals in the cytoplasm of astrocytes. The 
membrane bound indicator was not suitable for our investigation and set-up as it would 
need a confocal microscope to focus on labelled processes in order to distinguish them 
from deeper layers signal. Still, our data on Ca2+ indicators expressed in the cytoplasm 
of astrocytes gave us insight into the Ca2+ signalling behaviour evoked by peripheral 
fibres of different types. All fibre classes that were tested by stimulation showed to 
have at least a Ca2+ signalling increasing effect on astrocytes. We detected a 
suprathreshold for all tested fibre classes in astrocytes from 0.5 mA stimulation 
intensity on. Furthermore, our data showed that there was an impairment of astrocytic 
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Ca2+ signalling under neuropathic pain conditions in Aβ- and Aδ-fibre stimulation. This 
indicates that astrocytes from the spinal dorsal horn are involved in circuits of 
sensation of touch fibres and nociceptors as they reacted on neuronal activity from the 
periphery. Probably glutamate and ATP from pre-synapses, evoking action potentials 
in post-synaptic excitatory neurons also evoked Ca2+ signalling in astrocytes that were 
in close proximity of those synaptic clefts. The consequence of the initiation of Ca2+ 
signals in astrocytes through neuronal activity, induced by peripheral signal 
transmission into the spinal dorsal horn, might be recruitment of astrocytes for 
supporting the neurons by increased metabolism of glycogenesis, by increased 
gliotransmitter release and thus influencing the signal cascade in the dorsal horn and 
induction of plasticity changes of astrocytes to probably adjust to the neuronal 
surrounding which probably also changed in its plasticity (concerning excitatory and 
inhibitory neurons, which will be discussed in a later section). 
As we showed Ca2+ signals in the cytoplasm of astrocytes, the next step was to 
investigate the possibility of those signals entering the nucleus. In this thesis I have 
also shown, to my knowledge for the first time, evoked nuclear Ca2+ signals in 
astrocytes. With electrical stimulation of the dorsal roots, I was able to evoke those 
Ca2+ signals in spinal cord dorsal horn astrocytes robustly. All stimulated preferred 
fibres were shown to be responsible for downstream stimulation of nuclear Ca2+ 
signals in astrocytes. The lack of research on the topic of nuclear Ca2+ signalling in 
astrocytes is striking. As it is established by now that nuclear Ca2+ signals in neurons 
cause gene transcription and influence the plasticity of neurons, what might be the 
role of nuclear Ca2+ signals in astrocytes? It has been mentioned in a few publications 
already, that the key players of the nuclear Ca2+ pathway in neurons are also 
represented in astrocytes. For example (Liu, Dong, et al. 2017) showed that through 
Ca2+ signals CaMKIV is increased in order to regulate the expression of BDNF in 
astrocytes. This indicates already a potential role of nuclear Ca2+ signals in astrocytes 
similar to its role in neurons: gene transcription. This opens a whole new field of 
research: is it possible that stimulation evoked nuclear Ca2+ signals in astrocytes lead 
to gene transcription? And if so, would it mean a similar outcome as in neurons: 
change of plasticity for example? Thus, is nuclear Ca2+ signalling in astrocytes causing 
a plasticity change of astrocytes such as growth of endfeet? To investigate this matter 
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in more detail, gene expression levels specifically from astrocytes from the spinal 
dorsal horn under fibre stimulation have to be analysed.  
Considering the purpose of astrocytes, the support of neurons and its metabolism on 
glycolysis to provide lactate for neuronal consumption (Magistretti 2006; Morita et al. 
2019) it is possible that this mechanism is regulated by nuclear Ca2+ signalling. The 
activity from the fibres would evoke neuronal activity in the spinal dorsal horn, which 
would require an increased amount of energy. So in parallel, this activity would induce 
astrocytic nuclear Ca2+ signalling in order to start a process of increased metabolism 
for plasticity changes of astrocytes as well as of neurons so that further energy support 
would be facilitated. Taking into account that synaptic activity, which is definitely 
caused evoked through DR stimulation, also requires glucose utilisation as energy 
provider (neurometabolic coupling) (Magistretti 2006) and the fact that astrocytes play 
a major role in the providence of this energy source through glycolysis, it makes sense 
that astrocytes respond with Ca2+ signalling to also neuronal activity. To explain this 
further: the synaptic activity from neurons leads to glutamate and ATP release from 
neurons and astrocytes would react with Ca2+ signalling which would then induce 
mechanism that would lead to increased glycolysis to provide neurons as an answer 
to their increased activity. Furthermore, the nuclear Ca2+ signalling could also lead to 
gene induction to change plasticity structures in order to adapt to the new environment 
of neuronal circuits to ensure the frequent “assistance” to neurons in the spinal dorsal 
horn. 
 
4.2.2 Ca2+ signals in astrocytes under neuropathic pain conditions 
As we tested in this study the Ca2+ signalling at the time points where the defined 
chronic pain status, 24 h for chronic inflammatory pain and 7 d for neuropathic pain, 
already reached its peak of an established state of pain, it would further be of interest 
to test the Ca2+ signal changes in the development phase of chronic pain. As we see 
no difference in the Ca2+ signalling under chronic inflammatory pain in astrocytes, it 
might well be possible that the changes are required in the development and not in 
the maintenance of chronic inflammatory pain. The required plasticity changes might 
already been completed and not in need of increased Ca2+ signalling in astrocytes.  
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Also the changes of neuropathic pain in astrocytes in earlier phases, for example 24 
h or 48 h after SNI surgery, when the first mechanical hypersensitivity is measured in 
mice, would be of great interest. Would it show the same signalling behaviour as at 
later time points such as detected at seven days or would the development signalling 
differ from the established state? 
The data represented in this thesis indicate an important role of nuclear Ca2+ signalling 
in astrocytes in the context of neuropathic pain. The data show that there is a decrease 
of nuclear Ca2+ signalling especially for the stimulation of Aβ- and Aδ-fibres seven 
days after SNI surgery. That might indicate that astrocytes play a minor role in later 
phases of neuropathic pain in the context of gene transcription and plasticity changes 
and thus possible metabolism changes. These data have to be enforced by further 
experiments that would concentrate on the analysis of Ca2+ signals evoked by DR 
stimulation at different time points before and after 7 days after SNI surgery. As SNI 
means that nerves are cut and thus fewer signals reach the dorsal horn, it might 
explain the reduction of astrocytic Ca2+ signalling. Still, other time points have to be 
investigated as at some point excitatory neurons develop a hypersensitivity under 
neuropathic pain and the role of astrocytes in this context would be of high interest. In 
addition, the gene expression has to be analysed of astrocytes that were stimulated 
under neuropathic pain conditions. These data would give new interesting insights into 
the active role of astrocytes during neuropathic pain in the circuit of spinal dorsal horn 
cells driven and regulated by Ca2+ signalling. 
 
4.2.3 Ca2+ signalling in astrocytes under chronic inflammatory pain 
Under chronic inflammatory pain conditions there were no differences detected in the 
Ca2+ signalling behaviour between the CFA group and the PBS group of astrocytes. 
But this doesn’t mean, that there is no involvement of astrocytes in the development 
of chronic inflammatory pain. As mentioned above, other groups showed slight 
increase of morphological changes in form of astrogliosis under inflammatory pain 
conditions. The presented data just suggests that there is no role of Ca2+ signalling in 
the maintenance of chronic inflammatory pain in astrocytes when measured at a time 
point of 24 h after CFA injection, a time point when the chronic state of inflammatory 
pain is established. But at earlier time points, the development of this pain condition, 
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the Ca2+ signalling behaviour might still be different compared to its control group. 
Here more investigations have to be done. The Ca2+ signalling in astrocytes can be 
investigated at much earlier time points and the Ca2+ signalling dependent gene 
expression levels have to be identified at different time points after CFA injection and 
compared to PBS injected conditions. This would give even more insight into the 
possible role of Ca2+ signalling in astrocytes under chronic inflammatory pain 
conditions. 
Other approaches could concentrate on the sources of Ca2+ signalling induction. This 
could be investigated through blocking of different channels that are already known to 
be involved in astrocytic Ca2+ signalling, such as IP3 receptors to provide Ca2+ from 
the ER. Others might be ATP receptors, TRP channels and glutamate receptors. This 
could provide information about the driving force of DR evoked Ca2+ signalling in spinal 
dorsal horn astrocytes. This investigation could then also be extended to approach the 
occurrence of multiphasic Ca2+ responses. As we saw in our experiments, there were 
multiphasic responses after the initially evoked Ca2+ response in Ca2+ indicator 
expressing astrocytes. But we do not know the source of those multiphasic responses, 
nor do we know why they occur only occasionally. We were only able to describe them 
in a stimulation intensity dependent manner. We observed, that the multiphasic 
responses often occurred at a stimulation intensity of 0.5 – 1 mA in all stimulated fibre 
classes. In the end, this topic has to be explored in more detail. How can astrocytes 
react with more than one response onto fibre stimulation? Probably because they 
receive signals from other neurons from the dorsal horn as well. Ca2+ imaging with 
Ca2+ indicators, expressed in different cell types, could possibly give some insight into 
signal behaviour, concerning proximity of different neurons and astrocytes as well as 
their time dynamics. This could lead to conclusions about the influence of neuronal 
activity in excitatory and inhibitory neurons onto the Ca2+ signalling in astrocytes.  
 
4.2.4 Ca2+ signalling in Aldh1l1 mice 
During our work, we found that the used GFAP promoter for indicator expression in 
astrocytes is not as specific as we thought. Our data showed that the indicator under 
the GFAP promoter is also expressed in cells that were positive for NeuN labelling, 
suggesting that our recorded Ca2+ signals from previous experiments might have been 
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contaminated with neuronal Ca2+ signals. Even when the neurons that expressed the 
indicator had a weak GFP signal compared to astrocytes, which had much stronger 
labelling of the GFP expressing indicators, the possibility of neuronal Ca2+ signal 
contamination had to be taken serious. Our data from the Ca2+ imaging showed that 
the Ca2+ indicators in Aldh1l1 mice expressed in astrocytes only and not in neurons. 
The imaging further showed that the evoked signals resembled the signals from the 
WT mice where we used the expression of the indicators under the GFAP promoter. 
The data from the Aldh1l1 mouse-line support the detected dynamics of Ca2+ signals 
in astrocytes evoked by DR stimulation in the experiments from WT mice.  
In addition we showed that there is a possibility for more immediate Ca2+ signals than 
so far believed (Winship, Plaa, and Murphy 2007; Cali et al. 2008). More and more 
studies present the fast dynamics of Ca2+ signals in astrocytes endfeet and processes. 
This matter has to be investigated in greater detail by Ca2+ imaging using Ca2+ 
indicators in astrocytes tagged to the membrane in order to analyse the Ca2+ signals 
in the processes evoked by DR stimulation. For this study it is important to record with 
a high resolution set-up and recording with high frequencies, as the signals might be 
low and not reaching the astrocytic soma. Moreover, the resolution has to be as high 
as possible to exclude contamination of signals from astrocytes from deeper layers of 
the acute slice. 
 
4.3 Ca2+ signalling in parvalbumin-positive neurons under chronic 
inflammatory pain 
Excitatory neurons of the spinal cord dorsal horn exhibit enhanced Ca2+ signals in 
chronic inflammatory pain conditions (Simonetti et al. 2013). In addition, inhibitory 
neurons are impaired in their function and plasticity under chronic pain conditions 
(Basbaum et al. 2009). Only a few studies concentrated on the role of inhibitory 
neurons in the spinal dorsal horn under chronic inflammatory pain, suggesting that 
also under inflammatory pain there might be a disinhibition of inhibitory neurons (Lu et 
al. 2011). The evidence situation here is very thin, not many studies can be found on 
that topic. These facts led to the investigation of PV-positive cells in the spinal dorsal 
horn. 
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Our data showed that Ca2+ indicators expressed in pv-positivie cells, responded to DR 
stimulation to all the tested fibre types. Not only did they show evoked signals but they 
also showed spontaneous activity in different patterns and dynamics. We were not 
able to analyse the data of spontaneous activity as they were highly variable in their 
occurrence and dynamics. In addition, it might well be, that these different 
spontaneous activities represented artefact behaviour from the procedure of the acute 
slicing. Due to many different factors that might influence this spontaneous activity, for 
example stress, like the cutting procedure, the transportation from storage chambers 
to the set-up and quality of the tissue, it was not possible to analyse for a difference 
between CFA treated and PBS treated groups as the spontaneous activity also 
changed during stimulation. 
Under chronic inflammatory pain conditions the Ca2+ signals did not show any 
differences in PV-positive cells. Concerning the evoked signals, it can be, just as it 
was possible for the astrocytes Ca2+ signals, that the time point of the imaging is 
important to detect possible changes of Ca2+ signalling. Of course it can also not be 
excluded that under chronic inflammatory pain there are simply no changes in the Ca2+ 
signalling in PV-positive cells. In the end, there were no changes in the Ca2+ signalling 
24 h after chronic inflammatory pain induction in our experiments concerning PV-
positive neurons. 
Despite that, it is important to investigate in further detail the dynamics and 
characteristics of Ca2+ signals in PV-positive cells under chronic inflammatory pain at 
different time points after CFA injections as well as their gene expression levels, 
evoked by DR stimulation and driven by Ca2+ signalling. As already mentioned there 
are only a few studies on this topic and the role of inhibitory neurons under chronic 
inflammatory pain in the spinal dorsal horn needs to be more characterised in order to 
understand the mechanism of chronic inflammatory pain development and 
maintenance so that treatments can be developed. 
 
4.4 The role of Npas4 in chronic pain conditions 
Npas4 is an IEG which is induced by neuronal activity, to be more specific, by Ca2+ 
signalling. It is responsible for a homeostatic balance in favour of inhibition in the CNS. 
As we saw Ca2+ signals in PV-neurons induced through DR stimulation, we 
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investigated Npas4 in more detail, considering the special role of inhibitory neurons in 
the context of chronic pain. The analysis of Npas4 expression in the spinal dorsal horn 
of mice treated with CFA, we saw an immediate increase in the Npas4 expression at 
1 h after CFA injection. This level decreased back to baseline after 3 h. This indicates 
an immediate but not persistent requirement of Npas4 in the spinal dorsal horn under 
chronic inflammatory pain.  
In contrast, the analysis of Npas4 expression from spinal dorsal horn tissue under 
neuropathic pain induced through SNI surgery, showed a decrease compared to the 
contralateral side (not treated leg) at day 3 after surgery. This finding of decreased 
Npas4 levels makes sense as the fibres are cut from the periphery, so there would be 
no input to the CNS, thus no neuronal activity and no induction of Npas4. This showed 
that there is not such an immediate induction of Npas4 after SNI surgery compared to 
CFA injection. At day 10 after surgery, the Npas4 level is increased back to baseline 
level in the ipsilateral side. The question now would be, if the reduction of Npas4 in 
the early phase of neuropathic pain development plays an important role in the 
development of the persistent pain. Could a strong induction of Npas4 rescue the 
neuropathic pain development?  
 
It is clear, that inhibitory neurons play a crucial role in the neuropathic pain conditions. 
It has already been shown that inhibitory neurons are impaired in their function and 
their morphology under neuropathic pain models. As NPAS4 represents an important 
protein which controls through neuronal activity the plasticity changes that increase 
inhibitory control in the CNS, it is possible that chronic pain conditions involve impaired 
NPAS4 levels. This idea is supported by the fact that disinhibition is an important part 
of chronic pain formation (Petitjean et al. 2015) and combined with the fact that Npas4 
regulates the homeostatic balance in favour of inhibition. To investigate the exact role 
of NPAS4 in neuropathic pain conditions, NPAS4 levels were increased via an 
overexpression construct which was injected into the spinal cord dorsal horn of wild 
type mice. This construct induced increased protein levels of Npas4 in vitro and in 
vivo. Two weeks after the injection of this construct or its control construct, the mice 
got SNI surgery to induce neuropathic pain. The results showed that already 5 days 
after surgery the mice that were injected with the Npas4 overexpression construct 
showed a significant decrease of mechanical hypersensitivity compared to the group 
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that was injected with the control construct (Fig. 23 C). These findings show that Npas4 
indeed plays an important role in the development of neuropathic pain. My hypothesis 
is, that increased levels of Npas4 in the spinal dorsal horn prevent the development of 
disinhibition in the spinal cord circuits which would normally lead to chronic pain 
formation. Through the permanent high expression of Npas4 the neuronal inhibitory 
system can “counteract” against the increased excitability caused by the SNI surgery. 
Further experiments would concentrate on the role of Npas4 in chronic inflammatory 
pain. Here it would be possible to inject the dn-NPAS4 construct, which was already 
tested in vitro, into the spinal cord dorsal horn of wild type mice and induce CFA driven 
chronic inflammatory pain. As the relative gene expression in the first experiments 
(Fig. 16 A) showed that under CFA conditions Npas4 is increased, 1 h after injection. 
So here increased NPAS4 would maybe induce the chronic pain development. The 
suggested experiment would give some insight about the role of NPAS4 under chronic 
inflammatory pain conditions. The hypothesis would be that due to impaired function 
of NPAS4 through the dn-NPAS4 construct, there would be no induction of plasticity 
changes that are NPAS4 dependent.  
As the Ca2+ signalling of inhibitory neurons in the spinal dorsal horn showed no 
changes under chronic inflammatory pain, it is possible, that inhibitory neurons only 
are induced at the beginning of the CFA injection, at early time points, if at all. The 
relative gene expression levels of Npas4 after CFA injection doesn’t allow us 
unfortunately a differentiation between Npas4 levels in excitatory or inhibitory neurons. 
We were only able to make statements about the overall expression, independent from 
the cell type. Due to fibre activation, also inhibitory neurons are activated in the spinal 
dorsal horn, but there is no detectable difference between the CFA and the control 
group. But they seem to play no important role in the maintenance of chronic 
inflammatory pain.  
It seems that the Ca2+ regulation and thus the Npas4 expression is important 
especially for the Aβ-fibres, the touch sensory fibres. This is shown through the 
decreased Npas4 expression under neuropathic pain but also that the OENpas4 only 
rescued the mechanical but not the thermal hypersensitivity. This is also emphasised 
by the fact that Aβ-fibres mainly build synapses in lamina III where also many 
interneurons are placed to regulate the cell circuit in the dorsal horn. 
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Further approaches would be the testing of dn-Npas4 in acute inflammatory pain 
models, like formalin-induced acute inflammatory pain. The results would give 
information about possible differences of the role of Npas4 in acute and chronic pain 
conditions. In addition both pain models, the acute and the chronic inflammatory pain 
model, could also be tested with the OE-Npas4 construct. Permanent increased 
Npas4 level could possibly suppress the chronic pain development by strong inhibitory 
control of the CNS.  
4.5 Final conclusion and outlook 
Taken together, the results may lead to the suggestion that not C-fibres are 
responsible for chronic pain formation or maintenance, as they seem to not change 
their Ca2+ signalling and activity behaviour. It is very likely that the chronic and thus 
maladaptive pain formation occurs due to changes from the Aβ-fibres. All our data 
show that Aβ-fibres where in one way or another involved in pain formation or 
maintenance in different cell types. They changed their Ca2+ signalling behaviour 
during DR stimulation under chronic pain conditions. Under neuropathic pain 
conditions, they showed decreased Ca2+ signalling in astrocytes, in the cytosol as well 
as in the nucleus. 
In neurons, it was shown in our data that Ca2+ induced Npas4 expression was reduced 
under neuropathic pain conditions. This might indicate an impaired Ca2+ signalling in 
spinal dorsal horn neurons under neuropathic pain. The involvement of Aβ-fibres was 
shown in this context in the mechanical hypersensitivity under neuropathic pain, which 
means, that normally non-noxious touch stimuli were sensed by the mice as painful. 
NPAS4 overexpression rescued that phenotype as the pain threshold with OE-NPAS4 
injected mice was similar to the pre-SNI baseline. 
When we hurt ourselves, we tend to rub the injured place or mothers blow on a wound 
of children, to relieve their pain. This touch-sensory stimulation normally suppresses 
the pain sensation. Here might be the key to chronic pain formation. Taken the two 
pieces together, the “silencing” effect of Aβ (“touch”) fibres under chronic pain 
conditions to the spinal dorsal horn neurons seems to be disturbed as well as the 
regulation of inhibition through NPAS4. 
Ideas for therapeutic treatment could be to support of Aβ-fibres in their normal function 
as touch fibres and to ensure the function of NPAS4 in the dorsal horn circuits.  
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Appendix Figure 1: Visualisation of Ca2+ imaging. (A) Example of live picture of acute slice 
while expressing GFP signal from Ca2+ indicators (here GFAP:GCaMP5) at basal level. Round 
ROIs indicate cells that showed signals during stimulation procedure. Rectangular ROIs 
indicate background. (B) Representative example picture of expressed indicator 
(GFAP:GCaMP3.NLS.myc) in spinal dorsal horn during imaging before (i) and at stimulation 
(ii). Blue indicates low and red high intensity. Orientation of pictures: dorsal side up and ventral 
side down. Scale bar = 50 µm 
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Appendix Figure 2: Visualisation of catwalk. (A) Representative screenshot of a run way 
with mouse and the detected paws touching the surface. (B) Representative example graph 
showing the print surface of each paw touching the run way surface. (C) Representative graph 
showing the step intensity of each paw over time (s) of the mouse running along the run way. 
LF = left front paw, LH = left hind paw, RF = right front paw, RH = right hind paw. 
99 
 
5. References 
 
 
Abdallah, C. G., and P. Geha. 2017. 'Chronic Pain and Chronic Stress: Two Sides of the Same Coin?', 
Chronic Stress (Thousand Oaks), 1. 
Agulhon, C., T. A. Fiacco, and K. D. McCarthy. 2010. 'Hippocampal short- and long-term plasticity are 
not modulated by astrocyte Ca2+ signaling', Science, 327: 1250-4. 
Agulhon, C., J. Petravicz, A. B. McMullen, E. J. Sweger, S. K. Minton, S. R. Taves, K. B. Casper, T. A. 
Fiacco, and K. D. McCarthy. 2008. 'What is the role of astrocyte calcium in 
neurophysiology?', Neuron, 59: 932-46. 
Anderson, C. M., and M. Nedergaard. 2003. 'Astrocyte-mediated control of cerebral 
microcirculation', Trends Neurosci, 26: 340-4; author reply 44-5. 
Antal, M., T. F. Freund, and E. Polgar. 1990. 'Calcium-binding proteins, parvalbumin- and calbindin-D 
28k-immunoreactive neurons in the rat spinal cord and dorsal root ganglia: a light and 
electron microscopic study', J Comp Neurol, 295: 467-84. 
Araque, A., R. P. Sanzgiri, V. Parpura, and P. G. Haydon. 1999. 'Astrocyte-induced modulation of 
synaptic transmission', Can J Physiol Pharmacol, 77: 699-706. 
Bading, H. 2013. 'Nuclear calcium signalling in the regulation of brain function', Nat Rev Neurosci, 14: 
593-608. 
Basbaum, A. I., D. M. Bautista, G. Scherrer, and D. Julius. 2009. 'Cellular and molecular mechanisms 
of pain', Cell, 139: 267-84. 
Basbaum, A. I., and J. M. Braz. 2010. 'Transgenic Mouse Models for the Tracing of "Pain" Pathways.' 
in L. Kruger and A. R. Light (eds.), Translational Pain Research: From Mouse to Man (Boca 
Raton, FL). 
———. 2016. 'Cell transplants to treat the "disease" of neuropathic pain and itch', Pain, 157 Suppl 1: 
S42-7. 
Basbaum, A. I., and C. J. Woolf. 1999. 'Pain', Curr Biol, 9: R429-31. 
Bengtson, C. P., H. E. Freitag, J. M. Weislogel, and H. Bading. 2010. 'Nuclear calcium sensors reveal 
that repetition of trains of synaptic stimuli boosts nuclear calcium signaling in CA1 pyramidal 
neurons', Biophys J, 99: 4066-77. 
Berridge, M. J. 1998. 'Neuronal calcium signaling', Neuron, 21: 13-26. 
Bloodgood, B. L., N. Sharma, H. A. Browne, A. Z. Trepman, and M. E. Greenberg. 2013. 'The activity-
dependent transcription factor NPAS4 regulates domain-specific inhibition', Nature, 503: 
121-5. 
Boersma, K., M. Sodermark, H. Hesser, I. K. Flink, B. Gerdle, and S. J. Linton. 2019. 'Efficacy of a 
transdiagnostic emotion-focused exposure treatment for chronic pain patients with 
comorbid anxiety and depression: a randomized controlled trial', Pain, 160: 1708-18. 
Brenner, M., W. C. Kisseberth, Y. Su, F. Besnard, and A. Messing. 1994. 'GFAP promoter directs 
astrocyte-specific expression in transgenic mice', J Neurosci, 14: 1030-7. 
Cali, C., J. Marchaland, R. Regazzi, and P. Bezzi. 2008. 'SDF 1-alpha (CXCL12) triggers glutamate 
exocytosis from astrocytes on a millisecond time scale: imaging analysis at the single-vesicle 
level with TIRF microscopy', J Neuroimmunol, 198: 82-91. 
Chessell, I. P., J. P. Hatcher, C. Bountra, A. D. Michel, J. P. Hughes, P. Green, J. Egerton, M. Murfin, J. 
Richardson, W. L. Peck, C. B. Grahames, M. A. Casula, Y. Yiangou, R. Birch, P. Anand, and G. 
N. Buell. 2005. 'Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory 
and neuropathic pain', Pain, 114: 386-96. 
Christensen, R. K., R. Delgado-Lezama, R. E. Russo, B. L. Lind, E. L. Alcocer, M. F. Rath, G. Fabbiani, N. 
Schmitt, M. Lauritzen, A. V. Petersen, E. M. Carlsen, and J. F. Perrier. 2018. 'Spinal dorsal 
horn astrocytes release GABA in response to synaptic activation', J Physiol, 596: 4983-94. 
100 
 
Clapham, D. E. 2007. 'Calcium signaling', Cell, 131: 1047-58. 
Daniele, C. A., and A. B. MacDermott. 2009. 'Low-threshold primary afferent drive onto GABAergic 
interneurons in the superficial dorsal horn of the mouse', J Neurosci, 29: 686-95. 
De Vincenti, A. P., A. S. Rios, G. Paratcha, and F. Ledda. 2019. 'Mechanisms That Modulate and 
Diversify BDNF Functions: Implications for Hippocampal Synaptic Plasticity', Front Cell 
Neurosci, 13: 135. 
Decosterd, I., and C. J. Woolf. 2000. 'Spared nerve injury: an animal model of persistent peripheral 
neuropathic pain', Pain, 87: 149-58. 
Drdla, R., and J. Sandkuhler. 2008. 'Long-term potentiation at C-fibre synapses by low-level 
presynaptic activity in vivo', Mol Pain, 4: 18. 
Duan, B., L. Cheng, S. Bourane, O. Britz, C. Padilla, L. Garcia-Campmany, M. Krashes, W. Knowlton, T. 
Velasquez, X. Ren, S. Ross, B. B. Lowell, Y. Wang, M. Goulding, and Q. Ma. 2014. 
'Identification of spinal circuits transmitting and gating mechanical pain', Cell, 159: 1417-32. 
Echeverry, S., M. J. Rodriguez, and Y. P. Torres. 2016. 'Transient Receptor Potential Channels in 
Microglia: Roles in Physiology and Disease', Neurotox Res, 30: 467-78. 
Eder, A., and H. Bading. 2007. 'Calcium signals can freely cross the nuclear envelope in hippocampal 
neurons: somatic calcium increases generate nuclear calcium transients', BMC Neurosci, 8: 
57. 
Eng, L. F., R. S. Ghirnikar, and Y. L. Lee. 2000. 'Glial fibrillary acidic protein: GFAP-thirty-one years 
(1969-2000)', Neurochem Res, 25: 1439-51. 
Fiacco, T. A., C. Agulhon, S. R. Taves, J. Petravicz, K. B. Casper, X. Dong, J. Chen, and K. D. McCarthy. 
2007. 'Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory 
synaptic activity', Neuron, 54: 611-26. 
Gangadharan, V., and R. Kuner. 2013. 'Pain hypersensitivity mechanisms at a glance', Dis Model 
Mech, 6: 889-95. 
———. 2015. 'Unravelling Spinal Circuits of Pain and Mechanical Allodynia', Neuron, 87: 673-5. 
Gangadharan, V., R. Wang, B. Ulzhofer, C. Luo, R. Bardoni, K. K. Bali, N. Agarwal, I. Tegeder, U. 
Hildebrandt, G. G. Nagy, A. J. Todd, A. Ghirri, A. Haussler, R. Sprengel, P. H. Seeburg, A. B. 
MacDermott, G. R. Lewin, and R. Kuner. 2011. 'Peripheral calcium-permeable AMPA 
receptors regulate chronic inflammatory pain in mice', J Clin Invest, 121: 1608-23. 
Gaskin, D. J., and P. Richard. 2012. 'The economic costs of pain in the United States', J Pain, 13: 715-
24. 
Gassner, M., J. Leitner, D. Gruber-Schoffnegger, L. Forsthuber, and J. Sandkuhler. 2013. 'Properties of 
spinal lamina III GABAergic neurons in naive and in neuropathic mice', Eur J Pain, 17: 1168-
79. 
Gosselin, R. D., M. R. Suter, R. R. Ji, and I. Decosterd. 2010. 'Glial cells and chronic pain', 
Neuroscientist, 16: 519-31. 
Hagenston, A. M., and H. Bading. 2011. 'Calcium signaling in synapse-to-nucleus communication', 
Cold Spring Harb Perspect Biol, 3: a004564. 
Hansson, E. 2010. 'Long-term pain, neuroinflammation and glial activation', Scand J Pain, 1: 67-72. 
Hartzell, A. L., K. M. Martyniuk, G. S. Brigidi, D. A. Heinz, N. A. Djaja, A. Payne, and B. L. Bloodgood. 
2018. 'NPAS4 recruits CCK basket cell synapses and enhances cannabinoid-sensitive 
inhibition in the mouse hippocampus', Elife, 7. 
Haydon, P. G., and G. Carmignoto. 2006. 'Astrocyte control of synaptic transmission and 
neurovascular coupling', Physiol Rev, 86: 1009-31. 
Hyman, S. E., R. C. Malenka, and E. J. Nestler. 2006. 'Neural mechanisms of addiction: the role of 
reward-related learning and memory', Annu Rev Neurosci, 29: 565-98. 
Ikeda, H., T. Kiritoshi, and K. Murase. 2012. 'Contribution of microglia and astrocytes to the central 
sensitization, inflammatory and neuropathic pain in the juvenile rat', Mol Pain, 8: 43. 
Ji, R. R., T. Kohno, K. A. Moore, and C. J. Woolf. 2003. 'Central sensitization and LTP: do pain and 
memory share similar mechanisms?', Trends Neurosci, 26: 696-705. 
101 
 
Ji, R. R., and G. Strichartz. 2004. 'Cell signaling and the genesis of neuropathic pain', Sci STKE, 2004: 
reE14. 
Ji, Ru-Rong, Temugin Berta, and Maiken Nedergaard. 2013. 'Glia and pain: Is chronic pain a 
gliopathy?', Pain. 
Jonas, R., B. Namer, L. Stockinger, K. Chisholm, M. Schnakenberg, G. Landmann, M. Kucharczyk, C. 
Konrad, R. Schmidt, R. Carr, S. McMahon, M. Schmelz, and R. Rukwied. 2018. 'Tuning in C-
nociceptors to reveal mechanisms in chronic neuropathic pain', Ann Neurol, 83: 945-57. 
Kang, H., L. D. Sun, C. M. Atkins, T. R. Soderling, M. A. Wilson, and S. Tonegawa. 2001. 'An important 
role of neural activity-dependent CaMKIV signaling in the consolidation of long-term 
memory', Cell, 106: 771-83. 
Kim, S. K., H. Hayashi, T. Ishikawa, K. Shibata, E. Shigetomi, Y. Shinozaki, H. Inada, S. E. Roh, S. J. Kim, 
G. Lee, H. Bae, A. J. Moorhouse, K. Mikoshiba, Y. Fukazawa, S. Koizumi, and J. Nabekura. 
2016. 'Cortical astrocytes rewire somatosensory cortical circuits for peripheral neuropathic 
pain', J Clin Invest, 126: 1983-97. 
Lee, T. W., V. W. Tsang, and N. P. Birch. 2008. 'Synaptic plasticity-associated proteases and protease 
inhibitors in the brain linked to the processing of extracellular matrix and cell adhesion 
molecules', Neuron Glia Biol, 4: 223-34. 
Limback-Stokin, K., E. Korzus, R. Nagaoka-Yasuda, and M. Mayford. 2004. 'Nuclear 
calcium/calmodulin regulates memory consolidation', J Neurosci, 24: 10858-67. 
Liu, D., M. Zhang, X. Rong, J. Li, and X. Wang. 2017. 'Potassium 2-(1-hydroxypentyl)-benzoate 
attenuates neuronal apoptosis in neuron-astrocyte co-culture system through neurotrophy 
and neuroinflammation pathway', Acta Pharm Sin B, 7: 554-63. 
Liu, X. J., J. R. Gingrich, M. Vargas-Caballero, Y. N. Dong, A. Sengar, S. Beggs, S. H. Wang, H. K. Ding, P. 
W. Frankland, and M. W. Salter. 2008. 'Treatment of inflammatory and neuropathic pain by 
uncoupling Src from the NMDA receptor complex', Nat Med, 14: 1325-32. 
Liu, Y. Q., J. N. Dong, Q. X. Meng, P. Sun, and J. Zhang. 2017. 'Ultrasound for postoperative 
surveillance after mastectomy in patients with breast cancer: A retrospective study', 
Medicine (Baltimore), 96: e9244. 
Lu, J., T. Katano, D. Uta, H. Furue, and S. Ito. 2011. 'Rapid S-nitrosylation of actin by NO-generating 
donors and in inflammatory pain model mice', Mol Pain, 7: 101. 
Magistretti, P. J. 2006. 'Neuron-glia metabolic coupling and plasticity', J Exp Biol, 209: 2304-11. 
Marchi, S., S. Patergnani, S. Missiroli, G. Morciano, A. Rimessi, M. R. Wieckowski, C. Giorgi, and P. 
Pinton. 2018. 'Mitochondrial and endoplasmic reticulum calcium homeostasis and cell 
death', Cell Calcium, 69: 62-72. 
Mauceri, D., H. E. Freitag, A. M. Oliveira, C. P. Bengtson, and H. Bading. 2011. 'Nuclear calcium-
VEGFD signaling controls maintenance of dendrite arborization necessary for memory 
formation', Neuron, 71: 117-30. 
Maya-Vetencourt, J. F. 2013. 'Activity-dependent NPAS4 expression and the regulation of gene 
programs underlying plasticity in the central nervous system', Neural Plast, 2013: 683909. 
Melzack, R., and P. D. Wall. 1965. 'Pain mechanisms: a new theory', Science, 150: 971-9. 
Merskey, H. 1994. 'Logic, truth and language in concepts of pain', Qual Life Res, 3 Suppl 1: S69-76. 
Morita, M., H. Ikeshima-Kataoka, M. Kreft, N. Vardjan, R. Zorec, and M. Noda. 2019. 'Metabolic 
Plasticity of Astrocytes and Aging of the Brain', Int J Mol Sci, 20. 
Nestler, E. J., M. B. Kelz, and J. Chen. 1999. 'DeltaFosB: a molecular mediator of long-term neural and 
behavioral plasticity', Brain Res, 835: 10-7. 
Panatier, A., J. Vallee, M. Haber, K. K. Murai, J. C. Lacaille, and R. Robitaille. 2011. 'Astrocytes are 
endogenous regulators of basal transmission at central synapses', Cell, 146: 785-98. 
Papadia, S., P. Stevenson, N. R. Hardingham, H. Bading, and G. E. Hardingham. 2005. 'Nuclear Ca2+ 
and the cAMP response element-binding protein family mediate a late phase of activity-
dependent neuroprotection', J Neurosci, 25: 4279-87. 
102 
 
Peirs, C., S. P. Williams, X. Zhao, C. E. Walsh, J. Y. Gedeon, N. E. Cagle, A. C. Goldring, H. Hioki, Z. Liu, 
P. S. Marell, and R. P. Seal. 2015. 'Dorsal Horn Circuits for Persistent Mechanical Pain', 
Neuron, 87: 797-812. 
Petitjean, H., S. A. Pawlowski, S. L. Fraine, B. Sharif, D. Hamad, T. Fatima, J. Berg, C. M. Brown, L. Y. 
Jan, A. Ribeiro-da-Silva, J. M. Braz, A. I. Basbaum, and R. Sharif-Naeini. 2015. 'Dorsal Horn 
Parvalbumin Neurons Are Gate-Keepers of Touch-Evoked Pain after Nerve Injury', Cell Rep, 
13: 1246-57. 
Ramamoorthi, K., R. Fropf, G. M. Belfort, H. L. Fitzmaurice, R. M. McKinney, R. L. Neve, T. Otto, and Y. 
Lin. 2011. 'Npas4 regulates a transcriptional program in CA3 required for contextual memory 
formation', Science, 334: 1669-75. 
Ren, K., and M. A. Ruda. 1994. 'A comparative study of the calcium-binding proteins calbindin-D28K, 
calretinin, calmodulin and parvalbumin in the rat spinal cord', Brain Res Brain Res Rev, 19: 
163-79. 
Sandkuhler, J. 2009. 'Models and mechanisms of hyperalgesia and allodynia', Physiol Rev, 89: 707-58. 
Sandkuhler, J., J. G. Chen, G. Cheng, and M. Randic. 1997. 'Low-frequency stimulation of afferent 
Adelta-fibers induces long-term depression at primary afferent synapses with substantia 
gelatinosa neurons in the rat', J Neurosci, 17: 6483-91. 
Semyanov, A. 2019. 'Spatiotemporal pattern of calcium activity in astrocytic network', Cell Calcium, 
78: 15-25. 
Shepard, R., K. Heslin, P. Hagerdorn, and L. Coutellier. 2019. 'Downregulation of Npas4 in 
parvalbumin interneurons and cognitive deficits after neonatal NMDA receptor blockade: 
relevance for schizophrenia', Transl Psychiatry, 9: 99. 
Simonetti, M., A. M. Hagenston, D. Vardeh, H. E. Freitag, D. Mauceri, J. Lu, V. P. Satagopam, R. 
Schneider, M. Costigan, H. Bading, and R. Kuner. 2013. 'Nuclear calcium signaling in spinal 
neurons drives a genomic program required for persistent inflammatory pain', Neuron, 77: 
43-57. 
Sofroniew, M. V. 2009. 'Molecular dissection of reactive astrogliosis and glial scar formation', Trends 
Neurosci, 32: 638-47. 
Spiegel, I., A. R. Mardinly, H. W. Gabel, J. E. Bazinet, C. H. Couch, C. P. Tzeng, D. A. Harmin, and M. E. 
Greenberg. 2014. 'Npas4 regulates excitatory-inhibitory balance within neural circuits 
through cell-type-specific gene programs', Cell, 157: 1216-29. 
Srinivasan, R., B. S. Huang, S. Venugopal, A. D. Johnston, H. Chai, H. Zeng, P. Golshani, and B. S. 
Khakh. 2015. 'Ca(2+) signaling in astrocytes from Ip3r2(-/-) mice in brain slices and during 
startle responses in vivo', Nat Neurosci, 18: 708-17. 
Sun, X., and Y. Lin. 2016. 'Npas4: Linking Neuronal Activity to Memory', Trends Neurosci, 39: 264-75. 
Szokol, K., K. Heuser, W. Tang, V. Jensen, R. Enger, P. Bedner, C. Steinhauser, E. Tauboll, O. P. 
Ottersen, and E. A. Nagelhus. 2015. 'Augmentation of Ca(2+) signaling in astrocytic endfeet 
in the latent phase of temporal lobe epilepsy', Front Cell Neurosci, 9: 49. 
Takazawa, T., and A. B. MacDermott. 2010a. 'Glycinergic and GABAergic tonic inhibition fine tune 
inhibitory control in regionally distinct subpopulations of dorsal horn neurons', J Physiol, 
588: 2571-87. 
———. 2010b. 'Synaptic pathways and inhibitory gates in the spinal cord dorsal horn', Ann N Y Acad 
Sci, 1198: 153-8. 
Tang, W., K. Szokol, V. Jensen, R. Enger, C. A. Trivedi, O. Hvalby, P. J. Helm, L. L. Looger, R. Sprengel, 
and E. A. Nagelhus. 2015. 'Stimulation-evoked Ca2+ signals in astrocytic processes at 
hippocampal CA3-CA1 synapses of adult mice are modulated by glutamate and ATP', J 
Neurosci, 35: 3016-21. 
Tawfik, V. L., N. Nutile-McMenemy, M. L. LaCroix-Fralish, and J. A. DeLeo. 2007. 'Reprint of "efficacy 
of propentofylline, a glial modulating agent, on existing mechanical allodynia following 
peripheral nerve injury" [Brain Behav. Immun. 21 (2007) 238-246]', Brain Behav Immun, 21: 
677-85. 
103 
 
Todd, A. J. 2010. 'Neuronal circuitry for pain processing in the dorsal horn', Nat Rev Neurosci, 11: 
823-36. 
———. 2017. 'Identifying functional populations among the interneurons in laminae I-III of the spinal 
dorsal horn', Mol Pain, 13: 1744806917693003. 
Treede, R. D., W. Rief, A. Barke, Q. Aziz, M. I. Bennett, R. Benoliel, M. Cohen, S. Evers, N. B. Finnerup, 
M. B. First, M. A. Giamberardino, S. Kaasa, E. Kosek, P. Lavand'homme, M. Nicholas, S. 
Perrot, J. Scholz, S. Schug, B. H. Smith, P. Svensson, J. W. Vlaeyen, and S. J. Wang. 2015. 'A 
classification of chronic pain for ICD-11', Pain, 156: 1003-7. 
Tsuda, M. 2016. 'Microglia in the spinal cord and neuropathic pain', J Diabetes Investig, 7: 17-26. 
Ung, D. C., G. Iacono, H. Meziane, E. Blanchard, M. A. Papon, M. Selten, J. R. van Rhijn, R. Montjean, 
J. Rucci, S. Martin, A. Fleet, M. C. Birling, S. Marouillat, R. Roepman, M. Selloum, A. Lux, R. A. 
Thepault, P. Hamel, K. Mittal, J. B. Vincent, O. Dorseuil, H. G. Stunnenberg, P. Billuart, N. 
Nadif Kasri, Y. Herault, and F. Laumonnier. 2018. 'Ptchd1 deficiency induces excitatory 
synaptic and cognitive dysfunctions in mouse', Mol Psychiatry, 23: 1356-67. 
Volterra, A., N. Liaudet, and I. Savtchouk. 2014. 'Astrocyte Ca(2)(+) signalling: an unexpected 
complexity', Nat Rev Neurosci, 15: 327-35. 
Wang, X. M., G. F. Zhang, M. Jia, Z. M. Xie, J. J. Yang, J. C. Shen, and Z. Q. Zhou. 2019. 'Environmental 
enrichment improves pain sensitivity, depression-like phenotype, and memory deficit in 
mice with neuropathic pain: role of NPAS4', Psychopharmacology (Berl), 236: 1999-2014. 
Watanabe, S., M. Hong, N. Lasser-Ross, and W. N. Ross. 2006. 'Modulation of calcium wave 
propagation in the dendrites and to the soma of rat hippocampal pyramidal neurons', J 
Physiol, 575: 455-68. 
Winship, I. R., N. Plaa, and T. H. Murphy. 2007. 'Rapid astrocyte calcium signals correlate with 
neuronal activity and onset of the hemodynamic response in vivo', J Neurosci, 27: 6268-72. 
Woolf, C. J. 1983. 'Evidence for a central component of post-injury pain hypersensitivity', Nature, 
306: 686-8. 
Woolf, C. J., and M. W. Salter. 2000. 'Neuronal plasticity: increasing the gain in pain', Science, 288: 
1765-9. 
Wu, H., Y. Huang, X. Tian, Z. Zhang, Y. Zhang, Y. Mao, C. Wang, S. Yang, Y. Liu, W. Zhang, and Z. Ma. 
2019. 'Preoperative anxiety-induced glucocorticoid signaling reduces GABAergic markers in 
spinal cord and promotes postoperative hyperalgesia by affecting neuronal PAS domain 
protein 4', Mol Pain, 15: 1744806919850383. 
Yamamoto, T., P. A. Carr, K. G. Baimbridge, and J. I. Nagy. 1989. 'Parvalbumin- and calbindin D28k-
immunoreactive neurons in the superficial layers of the spinal cord dorsal horn of rat', Brain 
Res Bull, 23: 493-508. 
Zacharova, G., and J. Palecek. 2009. 'Parvalbumin and TRPV1 receptor expression in dorsal root 
ganglion neurons after acute peripheral inflammation', Physiol Res, 58: 305-9. 
Zacharova, G., D. Sojka, and J. Palecek. 2009. 'Changes of parvalbumin expression in the spinal cord 
after peripheral inflammation', Physiol Res, 58: 435-42. 
Zhang, S. J., M. Zou, L. Lu, D. Lau, D. A. Ditzel, C. Delucinge-Vivier, Y. Aso, P. Descombes, and H. 
Bading. 2009. 'Nuclear calcium signaling controls expression of a large gene pool: 
identification of a gene program for acquired neuroprotection induced by synaptic activity', 
PLoS Genet, 5: e1000604. 
Zhang, Z. J., B. C. Jiang, and Y. J. Gao. 2017. 'Chemokines in neuron-glial cell interaction and 
pathogenesis of neuropathic pain', Cell Mol Life Sci, 74: 3275-91. 
Zhao, L., and R. D. Brinton. 2003. 'Vasopressin-induced cytoplasmic and nuclear calcium signaling in 
embryonic cortical astrocytes: dynamics of calcium and calcium-dependent kinase 
translocation', J Neurosci, 23: 4228-39. 
 
